DRUGS related term(s) Crime; Pharmaceuticals

Addresses

State of the Union: President Biden, S257–S262 [7FE], H729–H735 [7FE]

Amendments

CDC: terminate requirement for proof of coronavirus vaccination for foreign travelers (H.R. 185), H750, H753, H754, H755, H756 [8FE]

——— terminate requirement for proof of coronavirus vaccination for foreign travelers (H.R. 185), consideration (H. Res. 97), H727 [7FE]

DEA: make permanent scheduling of fentanyl-related substances (H.R. 467), H2603, H2604 [25MY]

——— make permanent scheduling of fentanyl-related substances (H.R. 467), consideration (H. Res. 429), H2521 [23MY]

Dept. of Veterans Affairs: carry out clinical trial of effects of cannabis on certain health outcomes of adults with chronic pain and post-traumatic stress disorder (S. 326), S1307 [20AP], S1392 [26AP]

Diseases and disorders: eliminate coronavirus vaccine mandate on health care providers furnishing items and services under certain Federal health care programs (H.R. 497), consideration (H. Res. 75), H529 [31JA]

Immigration: secure U.S. borders and reform immigration policies (H.R. 2), consideration (H. Res. 383), H2192 [10MY]

NIST: coordinate science and research activities relative to illicit drugs containing xylazine, novel synthetic opioids, and other substances of concern (H.R. 1734), S2249, S2250 [22JN], H6087 [4DE]

Appointments

Senate Caucus on International Narcotics Control, S2035 [8JN]

U.S. Senate Caucus on International Narcotics Control, S835 [16MR]

Articles and editorials

Amazon Loophole Is Driving the Fentanyl Crisis, H5965 [29NO]

Are Biden’s Border Policies To Blame for Fentanyl Deaths? Experts Say No, H3082 [22JN]

COVID–19 Vaccines, Prior Infection Reduce Transmission of Omicron, H546 [31JA]

Fact Check—COVID–19 Vaccines Primarily Designed To Prevent Serious Illness, Death, H1164 [8MR]

Fentanyl Surge Started and Peaked Under Trump Despite GOP Blaming Biden, H2519 [23MY], H3080 [22JN]

Opioid Crisis—Critics Say Trump Fumbled Response to Another Deadly Epidemic, H2519 [23MY]

10 Myths Told by COVID Experts-And Now Debunked, H1167 [8MR]

Updated Covid Boosters Cut the Infection Risk From XBB.1.5 Subvariant by Nearly Half, CDC Finds, H545 [31JA]

Bills and resolutions

Abortion: ensure that women seeking chemical abortions are informed that it may be possible to reverse intended effects of abortion if they change their mind (see H.R. 983), H832 [10FE]

——— preempt State restrictions on dispensing medication abortion (see H.R. 2573), H1717 [10AP]

——— prohibit award of Federal funds to higher education institutions that host or are affiliated with student-based service site that provides abortion drugs or abortions to students or employees (see S. 16), S54 [23JA] (see H.R. 435), H250 [20JA]

——— prohibit chemical abortions (see H.R. 5806), H4854 [28SE]

——— prohibit chemical abortions performed without presence of health care provider (see H.R. 421), H249 [20JA]

Armed Forces: authorize use against those responsible for trafficking fentanyl or fentanyl-related substance into U.S. or carrying out related activities that cause regional destabilization in Western Hemisphere (see H.J. Res. 18), H234 [12JA]

——— establish certain protections for servicemembers, or cadets or midshipmen at military service academies, who refuse to receive coronavirus vaccination (see H.R. 434), H250 [20JA] (see H.R. 881), H780 [8FE]

——— establish certain remedies for certain individuals involuntarily separated from Armed Forces solely on basis of refusing to receive coronavirus vaccinations (see H.R. 3458), H2452 [18MY]

——— furnish stellate ganglion block to veterans and members with post-traumatic stress disorder (see H.R. 3023), H2117 [28AP]

——— provide remedies to members discharged or subject to adverse action under coronavirus vaccine mandate (see S. 29), S74 [24JA] (see H.R. 453), H276 [24JA]

——— reinstate servicemembers involuntarily separated solely due to refusal to receive coronavirus vaccination (see H.R. 297), H203 [11JA] (see H.R. 828), H708 [6FE]

Aviation: require interagency strategy for creating unified posture on counter-unmanned aircraft systems (C–UAS) capabilities and protections at U.S. international borders (see S. 1443), S1533 [4MY]

Biden, President: impeachment (see H. Res. 493), H2809 [12JN]

Biomedical Advanced Research and Development Authority: establish program to develop medical countermeasures for viral threats with pandemic potential (see S. 2093), S2185 [21JN] (see H.R. 3832), H2741 [5JN]

Bureau of Prisons: develop and implement strategy to interdict fentanyl and other synthetic drugs in mail at Federal correctional facilities (see H.R. 5266), H4203 [25AU]

Business and industry: establish patient protections with respect to highly rebated drugs (see H.R. 3285), H2342 [15MY]

——— prohibit distribution and receipt of rebates for prescription drugs (see S. 1217), S1256 [19AP]

——— require that retail list price for certain prescription drugs and biological products may not exceed average retail list price for such products among certain nations (see S. 1218), S1256 [19AP]

Cargo transportation: strengthen requirements relative to advance electronic information for cargo (see S. 1711), S1744 [18MY] (see H.R. 4023), H2807 [12JN]

Caribbean nations: authorize appropriations for Caribbean Basin Security Initiative, enhance U.S.-Caribbean security partnership, and prioritize disaster resilience (see S. 841), S825 [16MR] (see H.R. 1802), H1464 [27MR]

CDC: accelerate collection and publication of data on suicide and drug overdoses (see H.R. 4710), H3699 [18JY]

——— advance population research for chronic pain (see S. 2922), S4678 [26SE]

——— reauthorize certain substance use disorder prevention programs for pregnant and postpartum women (see S. 3370), S5692 [30NO]

——— reauthorize program of surveillance and education regarding infections associated with illicit drug use and other risk factors (see S. 2918), S4678 [26SE]

——— reauthorize surveillance and data collection for child, youth, and adult trauma (see H.R. 4057), H2883 [13JN]

——— terminate requirement for proof of coronavirus vaccination for foreign travelers (see S. 455), S426 [15FE] (see S. 641), S636 [2MR] (see H.R. 185), H104 [9JA]

——— terminate requirement for proof of coronavirus vaccination for foreign travelers (H.R. 185), consideration (see H. Res. 97), H737 [7FE]

Center for Biomedical Innovation and Development: establish (see S. 1441), S1533 [4MY]

Children and youth: prohibit certain coronavirus vaccination mandates and require parental consent for vaccination of minors (see S. 169), S172 [31JA]

——— prohibit manufacturing or distributing candy-flavored controlled substances for minors (see H.R. 757), H675 [2FE]

China: call on public, private, and nonprofit sectors to take action to counter ‘‘Made in China 2025’’ Plan (see H. Res. 697), H4381 [18SE]

——— condemn Chinese Communist Party for its role in fentanyl crisis and urge Biden administration to take certain actions to combat flow of fentanyl precursors from China to North America (see H. Res. 830), H5228 [1NO]

——— impose sanctions on Chinese producers of synthetic opioids and opioid precursors and hold Chinese officials accountable for spread of illicit fentanyl (see H.R. 3203), H2307 [11MY]

——— impose sanctions relative to export of fentanyl precursors (see H.R. 1171), H873 [24FE]

CIA: submit to Congress intelligence assessment on Sinaloa Cartel and Jalisco Cartel (see H.R. 6767), H6941 [13DE]

Coastal zones: extend U.S. customs waters (see S. 71), S98 [25JA] (see H.R. 529), H324 [25JA]

Colleges and universities: streamline process for institutions to research marijuana (see H.R. 3829), H2741 [5JN]

Commission on Strengthening the Domestic Pharmaceutical Supply Chain: establish (see H.R. 4449), H3159 [30JN]

Commission on the Federal Regulation of Cannabis: establish (see S. 2650), S3755 [27JY] (see H.R. 2598), H1724 [13AP]

Committee on Foreign Investment in the U.S.: increase oversight of foreign direct investment in U.S. agricultural land (see S. 1066), S1053 [29MR]

Consumers: reform prescription drug pricing and reduce out-of-pocket costs by ensuring consumers benefit from negotiated rebates by requiring coinsurance obligations be set as percentage of net price not list price (see H.R. 6856), H6997 [19DE]

Contraceptives: preempt State bans on prescription, provision, or use of drug, biological product, or device for contraception if approved, licensed, cleared, or otherwise authorized for human use by FDA for contraception (see H.R. 3471), H2452 [18MY]

Controlled Substances Act: amend to fix technical error in definitions (see S. 223), S204 [1FE] (see H.R. 455), H276 [24JA]

Courts: establish appropriate penalties for cocaine-related offenses (see S. 522), S457 [16FE]

——— give Federal courts additional discretion to determine whether pretrial detention is appropriate for defendants charged with nonviolent drug offenses in Federal criminal cases (see S. 1056), S1053 [29MR] (see H.R. 4361), H3142 [23JN]

——— increase mandatory minimum sentencing penalties for drug traffickers and dealers convicted for distribution of fentanyl (see S. 878), S859 [21MR]

Crime: amend laws relative to attempted murder and trafficking of fentanyl (see H.R. 4795), H3887 [20JY]

——— combat fentanyl crisis (see S. 2699), S3757 [27JY]

——— declare state of war between certain cartels and U.S. and make provision to prosecute same (see H.J. Res. 95), H4998 [11OC]

——— deter trafficking of illicit fentanyl and provide justice for victims (see S. 389), S313 [9FE] (see H.R. 2947), H2083 [27AP]

——— eliminate disparity in sentencing for crack and powder cocaine offenses (see S. 524), S457 [16FE] (see H.R. 1062), H852 [17FE]

——— exempt possession, sale, or purchase of fentanyl drug testing equipment from punishment under Federal drug paraphernalia laws (see H.R. 3563), H2498 [22MY]

——— prohibit certain acts related to fentanyl, analogues of fentanyl, and counterfeit substances (see S. 1475), S1566 [9MY] (see H.R. 4105), H2930 [14JN]

——— prohibit certain dangerous drone aircraft activity (see S. 157), S171 [31JA] (see H.R. 2944), H2083 [27AP]

——— prohibit Federal funding for any State, local, Tribal, or private entity that operates or controls injection center in violation of Controlled Substances Act (see H.R. 1355), H1112 [3MR]

——— prohibit knowing possession of pill press mold with intent to manufacture counterfeit substance in schedule I or II in capsule, tablet, and other form intended for distribution (see H.R. 1549), H1278 [10MR]

——— provide for punishment for knowing distribution of fentanyl if death results (see H.R. 1212), H914 [27FE]

——— punish distribution of fentanyl resulting in death as felony murder (see S. 380), S313 [9FE] (see H.R. 916), H823 [9FE]

——— reduce threshold for mandatory minimum penalties for certain fentanyl-related offenses (see H.R. 335), H233 [12JA]

——— require automatic sealing of certain minor nonviolent criminal records (see H.R. 2930), H2083 [27AP]

DEA: anniversary (see S. Res. 246), S2071 [13JN] (see H. Res. 501), H2884 [13JN]

——— authorize pharmacies to deliver certain controlled substances to administering practitioner in lieu of delivering such substances to ultimate user (see H.R. 4490), H3171 [6JY]

——— codify temporary scheduling order for fentanyl-related substances by adding fentanyl-related substances to schedule I of Controlled Substances Act (see S. 614), S569 [1MR] (see H.R. 4701), H3699 [18JY]

——— define currently accepted medical use with severe restrictions for controlled substances (see S. 689), S669 [7MR] (see H.R. 1393), H1148 [7MR]

——— establish National Center To Stop the Import of Illicit Synthetic Drugs (see H.R. 2616), H1725 [13AP]

——— include fentanyl-related substances under schedule I of Controlled Substances Act, designating they have high potential for abuse and no medical use (see S. 600), S568 [1MR] (see H.R. 568), H427 [26JA] (see H.R. 1291), H1048 [1MR] (see H.R. 1758), H1408 [23MR] (see H.R. 3629), H2595 [24MY]

——— make permanent scheduling of fentanyl-related substances (see S. 1141), S1090 [30MR] (see H.R. 171), H104 [9JA] (see H.R. 467), H276 [24JA] (see H.R. 1580), H1285 [14MR]

——— make permanent scheduling of fentanyl-related substances (H.R. 467), consideration (see H. Res. 429), H2498 [22MY]

——— provide for life imprisonment for certain offenses involving fentanyl (see H.R. 3215), H2307 [11MY]

——— require registrants to decline to fill certain suspicious orders (see H.R. 501), H322 [25JA]

——— review scheduling of buprenorphine-naloxone combination products under Controlled Substances Act (see H.R. 4053), H2883 [13JN]

Dept. of Agriculture: allow individuals with drug offenses to receive benefits under Supplemental Nutrition Assistance Program (see S. 1753), S1745 [18MY] (see H.R. 3479), H2453 [18MY]

——— exempt industrial hemp from certain requirements under hemp production program (see S. 980), S954 [27MR] (see H.R. 3755), H2664 [30MY]

——— expand medical expense deduction for elderly and disabled persons under Supplemental Nutrition Assistance Program (see S. 2432), S3459 [20JY] (see H.R. 4815), H3888 [20JY]

——— improve Supplemental Nutrition Assistance Program support for women, infants, and children impacted by substance use disorder (see H.R. 5312), H4211 [29AU]

——— prioritize projects that provide behavioral and mental health treatment services in selecting grantees under certain rural development programs and extend substance abuse disorder set-aside (see H.R. 4603), H3573 [13JY]

——— repeal prohibition for certain individuals convicted of felony offense to participate in hemp production (see H.R. 1428), H1149 [7MR]

Dept. of Defense: conduct detection, monitoring, and other operations in cyberspace to counter Mexican transnational criminal organizations engaged in certain activities that cross southern U.S. border (see S. 2715), S3757 [27JY]

——— develop plan to ensure adequate supply of medications for military health system (see H.R. 6903), H7007 [22DE]

——— develop strategy to counter fentanyl trafficking in U.S. (see S. 1619), S1678 [16MY] (see H.R. 3359), H2375 [16MY]

——— ensure drop boxes are maintained on military installations for deposit of unused prescription drugs (see H.R. 129), H102 [9JA]

——— establish grant program for using psychedelic substances to treat certain conditions (see H.R. 3684), H2636 [25MY]

——— establish pilot program to evaluate novel pharmaceutical manufacturing technologies to reduce reliance on foreign manufacturers for active pharmaceutical ingredients and key starting materials (see H.R. 6897), H7006 [22DE]

——— report on illicit drug use and overdoses by members of Armed Forces serving on active duty (see H.R. 5731), H4498 [26SE]

——— require responsiveness testing of Defense Logistics Agency pharmaceutical contracts (see S. 1057), S1053 [29MR] (see H.R. 5151), H4164 [4AU]

——— submit report evaluating beneficiary access to TRICARE network pharmacies (see H.R. 5150), H4164 [4AU]

——— submit report to Congress on overdoses among members of Armed Forces (see S. 1766), S1843 [31MY] (see H.R. 3751), H2664 [30MY]

Dept. of Education: develop and disseminate evidence-based curriculum for kindergarten through grade 12 on substance use disorders (see H.R. 3521), H2454 [18MY]

——— establish grant program to provide schools with opioid overdose reversal drugs and direct schools receiving Federal funds to report to certain Federal information systems any distribution of such drug (see H.R. 6251), H5466 [6NO]

——— establish State-Federal partnerships to provide students with debt-free college and provide Pell Grant eligibility to certain immigrants (see S. 1848), S2005 [7JN] (see H.R. 3923), H2778 [7JN]

——— prohibit imposition of coronavirus vaccine mandates by higher education institutions (see H.R. 1374), H1113 [3MR]

——— prohibit institutions of higher education from mandating coronavirus vaccines for students or staff (see H.R. 5634), H4455 [21SE]

——— study student mental health at institutions of higher education and issue guidance on compliance with Americans With Disabilities Act for mental health and substance use disorder policies (see S. 2163), S2223 [22JN] (see H.R. 3726), H2638 [25MY]

Dept. of HHS: allow expedited approval of generic prescription drugs and temporary importation of prescription drugs during noncompetitive drug markets and drug shortages (see S. 845), S825 [16MR]

——— allow grantees under HIV Health Care Services Program to allocate portion of such funding for services to individuals at risk of acquiring HIV (see S. 2107), S2221 [22JN]

——— authorize certain contracts and cooperative agreements with clinical laboratories for purposes of delivery of medical products to Strategic National Stockpile (see H.R. 3840), H2761 [6JN]

——— authorize fellowships under Minority Fellowship Program to be awarded for training for professionals in addiction medicine field (see S. 3145), S5213 [26OC]

——— authorize grants to ensure access for victims of family violence, domestic violence, and dating violence to substance use disorder treatment that allow families to remain together (see H.R. 6097), H5173 [26OC]

——— authorize loans and loan guarantees for planning, constructing, or renovating pediatric or adult mental health and substance use disorder treatment facilities (see H.R. 5804), H4854 [28SE]

——— authorize use of Preventive Health and Health Services Block Grants to purchase life-saving opioid antagonists for schools and provide training and education to students and teachers (see H.R. 4582), H3476 [12JY]

——— award grants to eligible entities to address maternal mental health conditions and substance use disorders relative to pregnant and postpartum individuals (see S. 1602), S1647 [15MY] (see H.R. 3312), H2344 [15MY]

——— award grants to regional biocontainment laboratories for maintaining surge capacity to respond to outbreaks of infectious diseases or acts of bioterrorism (see S. 2538), S3620 [26JY]

——— carry out national campaign to increase awareness of importance of maternal vaccinations for health of pregnant and postpartum individuals and their children (see H.R. 3348), H2346 [15MY]

——— clarify rules relative to drug discounts for covered entities (see S. 1133), S1090 [30MR]

——— clarify that grants for State and Tribal response to opioid use disorders may be used to address associated health conditions (see H.R. 4489), H3171 [6JY]

——— conduct demonstration program to test providing preferential treatment under Medicare, Medicaid, and Children’s Health Insurance Program for certain drugs and biologicals manufactured in U.S. (see S. 3311), S5540 [15NO]

——— conduct study on designation of biosimilar biological products as interchangeable (see S. 1522), S1602 [10MY]

——— conduct surveys of non-retail pharmacy drug prices (see S. 3245), S5402 [7NO]

——— continue Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria (see S. 2434), S3459 [20JY]

——— create plan for completing review of approved opioid analgesic drugs that considers public health effects of such opioid drugs (see S. 3557), S6057 [19DE]

——— delegate primary responsibility for maintaining Strategic National Stockpile to Assistant Secretary for Preparedness and Response (see H.R. 3837), H2761 [6JN]

——— eliminate coronavirus vaccine and mask requirement in Head Start programs (see H.R. 794), H677 [2FE]

——— ensure expenses relating to acquisition or use of devices to detect fentanyl, xylazine, and other emerging adulterant substances, including test strips are allowable expenses under certain grant programs (see S. 2976), S4759 [28SE] (see H.R. 5801), H4854 [28SE]

——— ensure references to opioid overdose reversal agents in grant programs are not limited to naloxone (see S. 2809), S4525 [14SE] (see H.R. 4007), H2807 [12JN]

——— ensure transparency and oversight of 340B drug discount program (see H.R. 3290), H2342 [15MY]

——— establish automated supply-chain tracking application that provides near real-time insight into amount of critical medical and health supplies available in Strategic National Stockpile (see H.R. 3577), H2499 [22MY]

——— establish education partnership programs between public schools and public health agencies to prevent misuse and overdose of synthetic opioids by youth (see H.R. 5625), H4454 [21SE]

——— establish fentanyl lethality awareness campaign, establish Federal Interagency Work Group on Fentanyl Contamination of Illegal Drugs, and provide grants to mitigate effects of drug misuse (see S. 1235), S1293 [20AP] (see H.R. 2867), H1947 [25AP]

——— establish grant program for family community organizations that provide support for individuals struggling with substance use disorder and their families (see S. 1810), S1982 [6JN] (see H.R. 3879), H2763 [6JN]

——— establish interactive online dashboard to improve public access to information about grant funding relative to mental health and substance use disorder programs (see S. 2444), S3459 [20JY] (see H.R. 4830), H3895 [24JY]

——— establish Office of Drug Manufacturing to manufacture certain generic drugs in order to reduce prices, increase competition, and address shortages in prescription drug market (see S. 3398), S5750 [5DE] (see H.R. 6607), H6144 [5DE]

——— establish program to develop antimicrobial innovations targeting most challenging pathogens and most threatening infections (see S. 1355), S1418 [27AP] (see H.R. 2940), H2083 [27AP]

——— establish program to reimburse health care providers for furnishing rabies postexposure prophylaxis to uninsured individuals (see H.R. 5782), H4853 [28SE]

——— establish program to support health care providers and pharmacies in providing discounted insulin products to uninsured individuals (see S. 954), S933 [23MR]

——— establish programs to address addiction and overdoses caused by illicit fentanyl and other opioids (see S. 1785), S1843 [31MY] (see H.R. 3375), H2376 [16MY]

——— establish reference prices for prescription drugs and require drug companies to offer drugs at such prices as condition of participation in Federal health programs (see S. 2044), S2145 [20JN] (see H.R. 4215), H2990 [20JN]

——— establish requirements relative to prescription drug benefits (see S. 1131), S1090 [30MR]

——— establish State insulin assistance programs, hold manufacturers accountable for excessive insulin price increases, and promote market competition to drive down prices (see S. 1497), S1566 [9MY] (see H.R. 3134), H2170 [9MY]

——— establish Substance Abuse and Mental Health Services Administration Center for Unhoused Individuals (see H.R. 4941), H4030 [26JY]

——— evaluate process by which interchangeable biological products are approved to be used in pharmaceuticals (see H.R. 1790), H1437 [24MR]

——— expand and clarify exclusion for orphan drugs under drug price negotiation program (see S. 3131), S5183 [25OC] (see H.R. 5539), H4380 [18SE]

——— expand drug price negotiation program (see H.R. 4895), H4028 [26JY]

——— extend health information technology assistance eligibility to behavioral health, mental health, and substance abuse professionals and facilities (see S. 2688), S3756 [27JY] (see S. 2688), H4157 [1AU]

——— extend requirement for State Medicaid plans to provide coverage for medication-assisted treatment (see S. 3136), S5212 [26OC] (see H.R. 3736), H2638 [25MY]

——— give preference for preventive health services project grants to States that allow trained individuals to carry and administer epinephrine (see H.R. 3910), H2778 [7JN]

——— improve access to pre-exposure prophylaxis (PrEP) to reduce transmission of HIV (see S. 2188), S2224 [22JN] (see H.R. 4392), H3150 [27JN]

——— improve Organ Procurement and Transplantation Network (see S. 1668), S1705 [17MY] (see S. 2404), S3458 [20JY] (see H.R. 2544), H1716 [10AP]

——— improve patient access to oral medications (see H.R. 4011), H2807 [12JN]

——— improve supply chain resiliency for critical drug products and ensure reserves of critical drugs and active pharmaceutical ingredients are maintained to prevent supply disruptions (see S. 2510), S3619 [26JY] (see H.R. 6802), H6984 [14DE]

——— increase access to medication for opioid overdose reversal (see S. 1373), S1418 [27AP]

——— increase access to mental health, substance use, and counseling services for first responders (see H.R. 6415), H5855 [14NO]

——— issue draft guidance to address non-addictive analgesics for chronic pain (see S. 3462), S5897 [11DE]

——— issue guidance on strategies under Medicaid and Children’s Health Insurance Program to increase mental health and substance use disorder care provider education, training, recruitment, and retention (see S. 3158), S5213 [26OC]

——— issue guidance on whether hospital emergency departments should implement fentanyl testing as routine procedure for patients experiencing overdose (see S. 3519), S5995 [14DE] (see H.R. 6600), H6143 [5DE]

——— make opioid treatment programs eligible for grants under Health Profession Opportunity Grant program (see H.R. 4788), H3887 [20JY]

——— make updates to National Vaccine Injury Compensation Program (see H.R. 5142), H4164 [4AU]

——— mitigate drug shortages and provide incentives for manufacturing of active pharmaceutical ingredients, excipients, medical devices, pharmaceuticals, and personal protective equipment (see H.R. 2707), H1885 [19AP]

——— prohibit from restricting direct access by health care facilities to medical countermeasures (see S. 2617), S3754 [27JY]

——— prohibit from treating pregnancy as illness for purposes of approving abortion drugs (see H.R. 6635), H6208 [6DE]

——— prohibit group health plans and health insurance issuers from entering into contracts that prevent or restrict access to drug pricing information available through consumer decision-support tools (see S. 1374), S1418 [27AP]

——— prohibit use of Federal funds to enforce rule on coronavirus vaccine and mask requirements for Head Start programs (see H.R. 1019), H838 [14FE]

——— prohibit use of Federal funds to purchase, procure, or distribute pipes or cylindrical objects intended to be used to smoke or inhale illegal scheduled substances (see S. 1520), S1602 [10MY]

——— prohibit use or declaration of public health emergency with respect to abortion (see H.R. 384), H242 [17JA]

——— promote price transparency in health care sector (see H.R. 5378), H4229 [8SE]

——— provide authority to suspend right to introduce certain persons or property into U.S. in interest of public health (see S. 1192), S1255 [19AP]

——— provide dedicated funding for health advocates to develop targeted outreach, event planning materials, and other resources for community organizations to utilize during National Recovery Month (see S. 2766), S4388 [12SE] (see H.R. 5418), H4263 [12SE] (see H.R. 5452), H4297 [13SE]

——— provide for appropriate cost-sharing for individuals of certain age for insulin products covered under private health plans and Medicaid (see H.R. 1587), H1285 [14MR]

——— provide for appropriate cost-sharing for insulin products covered under private health plans (see S. 954), S933 [23MR]

——— provide for clarity relative to duration of contracts for procurement of supplies for Strategic National Stockpile (see H.R. 4458), H3166 [3JY]

——— provide for stockpiles to ensure that all Americans have access to generic drugs at risk of shortage (see H.R. 405), H248 [20JA]

——— provide for suspension of entries and imports from designated countries to prevent spread of communicable diseases and import of certain controlled substances (see H.R. 801), H678 [2FE]

——— provide funding for trained school personnel to administer drugs and devices for emergency treatment of known or suspected opioid overdose (see S. 2946), S4720 [27SE] (see H.R. 3065), H2125 [2MY]

——— provide grants to medical and other health professional schools to expand or develop education and training programs for substance use prevention and treatment (see H.R. 4918), H4029 [26JY]

——— provide urgent acquisition and deployment authority for purposes of replenishing U.S. stockpiles (see S. 2055), S2145 [20JN]

——— reauthorize and expand technical assistance and support for recovery community organizations and peer support networks (see S. 3259), S5427 [8NO]

——— reauthorize and improve pilot program to support State medical stockpiles and ensure public health departments are consulted by Public Health Emergency Medical Countermeasures Enterprise (see S. 2080), S2185 [21JN]

——— reauthorize certain programs relative to public health security and all-hazards preparedness and response (see S. 2333), S2984 [18JY] (see H.R. 4697), H3698 [18JY]

——— reauthorize certain programs under Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act (see S. 1991), S2097 [14JN] (see H.R. 4102), H2930 [14JN]

——— reauthorize comprehensive opioid recovery centers (see H.R. 1502), H1247 [9MR]

——— reauthorize monitoring and education program regarding infections associated with illicit drug use and other risk factors (see H.R. 4100), H2930 [14JN]

——— reauthorize pilot program for public health laboratories to detect fentanyl and other synthetic opioids (see H.R. 4063), H2883 [13JN]

——— reauthorize program for strengthening communities of recovery for individuals with substance use disorders (see S. 3424), S5807 [6DE]

——— reauthorize program of preventing overdoses of controlled substances (see H.R. 4099), H2930 [14JN]

——— remove certain liability protections for certain biological products and other drugs if sponsor thereof fails to disclose to public all non-exempt data within biological product file or drug application (see H.R. 5773), H4713 [27SE]

——— require drug manufacturers to include printed inserts containing drug information when they ship their products to pharmacies (see H.R. 1173), H873 [24FE]

——— require drug manufacturers to submit transparency and justification report prior to increasing certain drug prices (see S. 935), S909 [22MR]

——— require funds to be set aside for opioid reversal agent administration training in schools (see H.R. 5652), H4455 [21SE]

——— specify duration of contracts, grants, cooperative agreements, or other transactions awarded or entered into with Biomedical Advanced Research and Development Authority (see H.R. 4459), H3166 [3JY]

——— support endemic fungal disease research, incentivize valley fever vaccine development, and discover new antifungal therapies and diagnostics to fight infections such as Valley Fever (see S. 3464), S5919 [12DE] (see H.R. 6731), H6859 [12DE]

Dept. of Homeland Security: address fentanyl being smuggled across border with Mexico (see H.R. 943), H824 [9FE]

——— authorize to perform certain drug enforcement functions (see H.R. 5713), H4497 [26SE]

——— designate illicit fentanyl as weapon of mass destruction (see H.R. 3666), H2635 [25MY]

——— develop comprehensive plan to identify, deploy, and integrate emerging technologies to achieve greater situational awareness along northern and southern borders of U.S. (see H.R. 6391), H5728 [13NO]

——— enhance capabilities for outbound inspections at southern land border (see S. 1897), S2028 [8JN]

——— establish Border Enforcement Security Task Force unit to investigate transnational criminal organization arms smuggling across border between U.S. and Mexico (see H.R. 331), H232 [12JA]

——— establish Cross-Border Financial Crime Center to combat illicit cross-border financial activity and improve U.S. Immigration and Customs Enforcement Trade Transparency Unit program (see S. 3384), S5693 [30NO]

——— establish integrated border intelligence analytical cell and Joint Task Force to combat transnational organizations exploiting migration surges and strengthen cross-border partnerships (see H.R. 6392), H5728 [13NO]

——— establish Joint Task Force to Combat Opioid Trafficking (see H.R. 3658), H2596 [24MY]

——— improve border security through regular assessments and evaluations of Checkpoint Program Management Office and effective training of U.S. Border Patrol agents regarding drug seizures (see S. 2367), S3147 [19JY]

——— improve collection of intelligence relative to activities by drug trafficking organizations in certain foreign countries (see H.R. 597), H489 [27JA]

——— investigate and remove aliens providing false information about drug-related grounds of inadmissibility (see H.R. 5178), H4171 [8AU]

——— making continuing appropriations for certain employees and contractors of U.S. Customs and Border Protection and U.S. Immigration and Customs Enforcement in event of Government shutdown (see S. 2999), S4826 [29SE] (see H.R. 5841), H4909 [29SE]

——— publish report on number of migrants at each port of entry apprehended, paroled, or granted work authorization (see S. 3187), S5315 [1NO] (see H.R. 6523), H6049 [30NO]

——— require comprehensive southern border strategy (see H.R. 3508), H2454 [18MY]

——— require U.S. Customs and Border Protection to annually review and update policies and manuals to ensure uniform inspection practices along U.S. border (see S. 3112), S5143 [24OC]

——— restrict flow of illicit drugs into U.S. (see S. 1464), S1534 [4MY]

——— secure southern border, reform asylum system, provide earned path to citizenship, make e-verify mandatory, and establish American Worker Fund using immigrant restitution payments (see H.R. 3599), H2545 [23MY]

——— suspend entry of illegal aliens in response to fentanyl public health crisis (see S. 1532), S1603 [10MY]

——— terminate requirement for proof of coronavirus vaccination for foreign travelers (see H.R. 3094), H2134 [5MY]

Dept. of HUD: authorize grant program to assist State and local governments, continuums of care, and community-based organizations that administer health and homelessness services to better coordinate those services (see S. 3165), S5229 [30OC] (see H.R. 773), H676 [2FE]

——— authorize mortgage insurance for certain treatment facilities (see H.R. 5648), H4455 [21SE]

——— prohibit limiting or restricting award of Continuum of Care program funds to providers who require benefit recipients participate in certain wraparound services (see H.R. 3405), H2423 [17MY]

——— reauthorize and expand pilot program to help individuals in recovery from substance use disorders become stably housed (see H.R. 5137), H4164 [4AU]

Dept. of Justice: allow for civil and criminal actions against certain providers of interactive computer services relative to fentanyl trafficking (see S. 2264), S2360 [12JY]

——— authorize compensation for victims of illicit fentanyl poisoning (see H.R. 624), H509 [30JA]

——— authorize grant programs to combat fentanyl poisonings (see H.R. 6144), H5228 [1NO]

——— authorize grants to States and units of local government to reduce financial and administrative burden of expunging convictions for cannabis offenses (see H.R. 2677), H1845 [18AP]

——— authorize use of grants to provide training for first responders on use of containment devices to prevent exposure to fentanyl and other potentially lethal substances and for purchasing such devices (see S. 261), S230 [2FE] (see H.R. 795), H678 [2FE]

——— expand Comprehensive Opioid Abuse Grant Program (see H.R. 6243), H5465 [6NO]

——— improve data on opioid-related overdoses and award grants to local law enforcement agencies in communities with high rates of overdoses (see S. 983), S954 [27MR] (see H.R. 3150), H2171 [9MY]

——— improve treatment courts (see S. 2593), S3753 [27JY]

——— permit defendants convicted of certain drug offenses to be eligible for reduced sentences (see S. 1247), S1293 [20AP] (see H.R. 50), H99 [9JA]

——— prioritize veterans court treatment programs that ensure equal access for racial and ethnic minorities and women (see H.R. 232), H149 [10JA]

——— provide for Comprehensive Opioid, Stimulant, and Substance Abuse Program pilot program for local law enforcement agencies in rural areas to purchase naloxone to prevent and reduce opioid overdose deaths (see H.R. 4431), H3158 [30JN]

——— provide grants for drug disposal sites (see H.R. 5615), H4454 [21SE]

——— provide grants to State and local law enforcement agencies to purchase chemical screening devices to detect dangerous drugs and train personnel on use of such devices (see S. 1507), S1567 [9MY] (see H.R. 3148), H2170 [9MY]

——— provide outreach regarding fentanyl, expand Comprehensive Opioid Abuse Grant Program and addiction treatment and recovery services, and enhance penalties for certain offenses involving counterfeit pills (see H.R. 3570), H2499 [22MY] (see H.R. 4272), H3107 [22JN]

——— reauthorize residential substance use disorder treatment program (see H.R. 238), H149 [10JA]

——— require electronic communication service providers and remote computing services to report unlawful sale and distribution of controlled substances (see S. 1080), S1088 [30MR]

——— require reporting of suspicious transmissions in order to assist in criminal investigations and counterintelligence activities relative to terrorism, serious drug offenses, and violent crimes (see S. 147), S147 [30JA]

——— use lawfully forfeited drug seizures to increase border security (see H.R. 776), H676 [2FE]

Dept. of Labor: conduct study on fiduciary duties of pharmacy benefit managers (see S. 3330), S5540 [15NO]

——— enhance technical assistance and support for communities impacted by substance use disorders (see H.R. 6587), H6143 [5DE]

——— issue guidance and regulations regarding opioid overdose reversal medication and employee training (see S. 2948), S4720 [27SE] (see H.R. 5420), H4263 [12SE]

——— issue occupational safety and health standard that requires employers to keep opioid overdose reversal drugs onsite and develop and implement training plans to respond to drug overdose emergencies (see H.R. 6243), H5465 [6NO]

——— prohibit issuance of emergency temporary standard requiring employers to ensure employees receive coronavirus vaccine or testing (see H.R. 526), H323 [25JA]

Dept. of State: assess role of Chinese Communist Party in distribution of fentanyl in U.S. (see H.R. 3598), H2545 [23MY]

——— designate Mexican cartels and other transnational criminal organizations as foreign terrorist organizations (see S. 1048), S1053 [29MR]

——— designate Mexican drug cartels as foreign terrorist organizations (see H. Res. 216), H1249 [9MR]

——— develop strategy on efforts to strengthen subnational cooperation between U.S. and Mexico to combat trafficking of fentanyl and other synthetic opioids (see H.R. 2789), H1909 [20AP]

——— impose sanctions on Chinese pharmaceutical companies and certain cartels that traffic fentanyl (see S. 2059), S2145 [20JN]

——— impose sanctions relative to illicit captagon trafficking (see H.R. 4681), H3639 [17JY]

——— impose sanctions with respect to Chinese officials determined to be involved in Mexican fentanyl trade (see H.R. 5448), H4296 [13SE]

——— include information in International Narcotics Control Strategy Report on improvements by countries in combating narcotics-related money laundering and report on consistency of Bank Secrecy Act examinations (see H.R. 5523), H4379 [18SE]

——— limit funding for international narcotics control and law enforcement (see H.R. 2351), H1639 [29MR]

——— prioritize efforts with Mexico to combat international trafficking in precursor chemicals and synthetic drugs and impose sanctions on Chinese producers of illicit drugs or their means of production (see S. 1689), S1743 [18MY]

——— report to Congress on designation of MS–13, Queen Nation, Sinaloa, Cartel Jalisco Nueva Generacion, and Beltran Leyva Organization as foreign terrorist organizations (see H.R. 2633), H1758 [17AP]

——— submit report on designation of Reynosa/Los Metros faction of Gulf Cartel, Jalisco New Generation Cartel, Sinaloa Cartel, and Cartel Del Noreste faction of Los Zetas as foreign terrorist organizations (see S. 698), S714 [8MR] (see H.R. 1564), H1279 [10MR]

Dept. of the Treasury: impose sanctions with respect to trafficking of illicit fentanyl and its precursors by transnational criminal organizations, including cartels (see S. 1271), S1340 [25AP] (see H.R. 3333), H2346 [15MY]

——— impose special measures on transactions relative to illicit fentanyl trafficking (see H.R. 3231), H2308 [11MY]

——— provide authority to take special measures against certain entities outside of U.S. of primary money laundering concern in connection with illicit fentanyl and narcotics financing (see H.R. 3244), H2308 [11MY]

——— require Financial Crimes Enforcement Network to publish annual Financial Trend Analysis describing illicit financial schemes and methods related to trafficking of fentanyl and other synthetic opioids (see H.R. 6434), H5892 [15NO]

Dept. of Veterans Affairs: allow veterans to use, possess, or transport medical marijuana and to discuss use of medical marijuana with departmental physicians as authorized by State or Tribal law (see S. 1204), S1255 [19AP] (see H.R. 2682), H1845 [18AP]

——— authorize health care providers to provide recommendations and opinions to veterans regarding participation in State marijuana programs (see H.R. 2431), H1691 [30MR]

——— carry out clinical trial of effects of cannabis on certain health outcomes of adults with chronic pain and post-traumatic stress disorder (see S. 326), S311 [9FE] (see H.R. 1003), H837 [14FE]

——— conduct and support research on efficacy and safety of medicinal marijuana (see H.R. 3584), H2500 [22MY]

——— conduct review of deaths of certain veterans who committed suicide (see H.R. 4400), H3157 [30JN]

——— conduct review on opioid overdose deaths among veterans (see H.R. 6353), H5668 [9NO]

——— establish patient outreach system relative to mental health care (see H.R. 492), H277 [24JA]

——— expand access to Veterans Community Care Program to include certain veterans seeking mental health or substance-use services (see S. 1745), S1745 [18MY] (see H.R. 3554), H2456 [18MY]

——— prohibit denial of benefits due to participation in State-approved marijuana program (see H.R. 394), H243 [17JA]

Depts. of HHS and State: formulate strategy to secure support from foreign countries, multilateral organizations, and others to facilitate development and commercialization of qualified pandemic or epidemic products (see H.R. 1305), H1048 [1MR]

Diseases and disorders: eliminate coronavirus vaccine mandate on health care providers furnishing items and services under certain Federal health care programs (see H.R. 497), H322 [25JA]

——— eliminate coronavirus vaccine mandate on health care providers furnishing items and services under certain Federal health care programs (H.R. 497), consideration (see H. Res. 75), H574 [31JA]

——— facilitate development of treatments for cancers (see S. 642), S636 [2MR] (see H.R. 1780), H1437 [24MR]

——— mitigate effects of coronavirus pandemic on incentives for development of orphan drugs (see H.R. 1805), H1464 [27MR]

——— nullify certain executive orders relative to coronavirus vaccine mandates and prohibit Dept. of Labor from issuing rule mandating coronavirus vaccination (see H.R. 119), H102 [9JA]

——— prohibit any entity that receives Federal funding from coronavirus relief packages from mandating employees receive coronavirus vaccine (see H.R. 117), H102 [9JA]

——— prohibit use of Federal funds to propose, establish, implement, or enforce any requirement that individuals wear masks or other face coverings, or be vaccinated, to prevent spread of coronavirus (see H.R. 74), H100 [9JA]

——— prohibit vaccination mandates for coronavirus (see S. 167), S172 [31JA] (see H.R. 403), H248 [20JA]

——— protect against seasonal and pandemic influenza (see S. 3219), S5338 [2NO] (see H.R. 5846), H4909 [29SE]

——— recognize critical role that President’s Emergency Plan for AIDS (PEPFAR) has played in global fight against HIV/AIDS (see S. Res. 139), S1091 [30MR]

District of Columbia: prohibit use of Federal and local funds for coronavirus vaccine mandate in District of Columbia schools and repeal related legislation enacted by District of Columbia Council (see S. 165), S172 [31JA]

Drug abuse: provide for opioid use disorder prevention, recovery, and treatment (see H.R. 4531), H3204 [11JY]

Drugs: establish incentive pay for positions requiring specialized skills to combat fentanyl trafficking (see S. 1175), S1210 [18AP]

——— issue guidance and regulations regarding opioid overdose reversal medication and employee training (see H.R. 5420), H4263 [12SE]

Employment: void existing non-compete agreements for any employee fired for not complying with employer’s coronavirus vaccine mandate (see H.R. 527), H323 [25JA]

Executive Office of the President: limit funding for Office of National Drug Control Policy and other Federal drug control programs (see H.R. 2073), H1629 [29MR]

——— limit funding for Office of National Drug Control Policy High Intensity Drug Trafficking Areas Program (see H.R. 2072), H1629 [29MR]

——— limit funding for Office of National Drug Control Policy salaries and expenses (see H.R. 2071), H1629 [29MR]

FAA: include medications and medical equipment for emergency treatment of known or suspected opioid overdose in aircraft emergency medical kits (see H.R. 3616), H2546 [23MY]

——— reinstate pilots fired or forced to resign because of coronavirus vaccine mandate (see S. 3413), S5807 [6DE] (see H.R. 6627), H6207 [6DE]

Families and domestic relations: ensure comprehensive wraparound services for families impacted by substance use disorders (see S. 3006), S4916 [3OC] (see H.R. 5866), H4950 [2OC]

FDA: allow digital communication of prescribing information for drugs, including biological products (see S. 2916), S4678 [26SE] (see H.R. 1503), H1248 [9MR]

——— allow for hemp-derived cannabidiol and hemp-derived cannabidiol containing substances in dietary supplements and food (see S. 2451), S3459 [20JY] (see H.R. 4849), H3948 [25JY]

——— allow rejection of citizen petition if it is believed primary purpose of petition is to delay approval of pending drug application and refer such petitioners to FTC (see S. 1067), S1053 [29MR]

——— allow women greater access to wider range of self-administered contraceptives (see H.R. 1512), H1248 [9MR]

——— amend laws relative to 180-day exclusivity period (see S. 1114), S1089 [30MR]

——— amend mission statement to require agency to address nation’s prescription opioid addiction epidemic (see S. 604), S568 [1MR]

——— clarify process for denying certain petitions whose primary purpose is to delay approval of application submitted relative to certain drugs (see H.R. 3030), H2118 [28AP]

——— deny approval of new drug application for opioid analgesic drug on basis of such drug not being clinically superior to other commercially available drugs (see S. 607), S568 [1MR] (see H.R. 1375), H1113 [3MR]

——— determine whether to permit use of enriched enrollment randomized withdrawal methodology relative to clinical trials (see S. 2737), S4270 [7SE]

——— encourage sponsors of oral contraceptive drugs to submit applications for approval of such drugs as over-the-counter (see H.R. 4626), H3574 [13JY]

——— enhance drug manufacturing amount information reporting (see H.R. 3810), H2740 [5JN]

——— ensure patients have access to certain urgent-use compounded medications (see H.R. 167), H104 [9JA]

——— establish additional authorities regarding conduct of pediatric investigations of molecularly targeted drugs to treat cancer (see S. 2897), S4654 [21SE] (see H.R. 3433), H2425 [17MY]

——— establish emerging pathogen preparedness program to improve regulatory oversight of medical countermeasures for future pandemics (see S. 2329), S2461 [13JY]

——— establish postmarket reporting requirements for pharmaceuticals (see S. 3143), S5213 [26OC] (see H.R. 6112), H5174 [26OC]

——— establish procedures relative to approval of opioid drugs (see S. 603), S568 [1MR]

——— establish process to allow holders of abbreviated new generic drug applications to make labeling changes to include new or updated safety-related information (see H.R. 4134), H2932 [14JN]

——— establish requirements for purchasing certain generic drugs from manufacturers who produce drug domestically (see S. 2683), S3756 [27JY]

——— establish special rules allowing generic manufacturers to sue brand-name manufacturers who overstate applications concerning method of use patents (see S. 1128), S1090 [30MR]

——— establish time-limited conditional approval pathway, subject to specific obligations, for certain drugs and biological products (see S. 1906), S2029 [8JN] (see H.R. 4408), H3157 [30JN]

——— expand certain authorities relative to recall of controlled substances to apply with respect to all drugs (see H.R. 2500), H1707 [6AP]

——— expand tropical disease product priority review voucher program to encourage prevention and treatment of coccidioidomycosis (see S. 3220), S5338 [2NO] (see H.R. 6227), H5404 [3NO]

——— expressly authorize use of certain grants to implement substance use disorder and overdose prevention activities relative to fentanyl and xylazine test strips (see H.R. 4106), H2930 [14JN]

——— improve priority review process of human drug applications to encourage treatment for agents that present national security threats (see S. 1122), S1090 [30MR] (see H.R. 5708), H4497 [26SE]

——— improve regulation of abortion drugs by prohibiting approval of new drugs, preventing labeling changes of existing drugs, and limiting dispensing of drugs remotely, by mail, or telemedicine (see S. 95), S120 [26JA] (see H.R. 427), H249 [20JA]

——— improve requirements for making determination of interchangeability of biological product and its reference product (see S. 2305), S2460 [13JY]

——— issue guidance on considerations for conducting clinical trials for psychedelic assisted therapy (see H.R. 4242), H3070 [21JN]

——— limit exclusive approval or licensure of orphan drugs (see H.R. 456), H276 [24JA]

——— make certain changes relative to approval of abbreviated applications for approval of new animal drugs (see H.R. 1683), H1300 [21MR]

——— make hemp, cannabidiol derived from hemp, and any other ingredient derived from hemp lawful for use as dietary ingredients in dietary supplements (see H.R. 1629), H1292 [17MR]

——— modernize methods of authenticating controlled substances in pharmaceutical distribution supply chain (see H.R. 4988), H4138 [27JY]

——— nullify modifications made to risk evaluation and mitigation strategy for abortion pill mifepristone (see H.R. 383), H242 [17JA] (see H.R. 5850), H4909 [29SE]

——— permit manufacturers to provide additional warnings on generic drugs in same manner as brand name drugs (see S. 2886), S4654 [21SE]

——— preserve access to abortion medications (see S. 237), S229 [2FE] (see H.R. 767), H676 [2FE] (see H. Con. Res. 33), H1725 [13AP]

——— prohibit sale of poppy seeds, or food that contains poppy seeds, with unsafe levels of certain opiates (see S. 3354), S5674 [29NO] (see H.R. 6512), H5983 [29NO]

——— provide for mandatory recall authority over regulated drugs and homeopathic products (see H.R. 3688), H2636 [25MY]

——— provide for notification by manufacturers of critical essential medicines of increased demand of such drugs (see S. 2362), S2985 [18JY] (see H.R. 3008), H2117 [28AP]

——— provide increased transparency in generic drug applications (see S. 775), S771 [14MR] (see H.R. 3839), H2761 [6JN]

——— provide marketing reciprocity to certain drugs, biological products, and medical devices authorized to be lawfully marketed abroad (see S. 1712), S1744 [18MY] (see H.R. 3532), H2455 [18MY]

——— reaffirm authority to approve drugs for abortion care (see H. Res. 309), H1887 [19AP]

——— reauthorize user fee programs relating to new animal drugs and generic new animal drugs (see S. 1844), S2005 [7JN] (see H.R. 1418), H1149 [7MR]

——— repeal authority to require that drugs be dispensed only upon prescription (see H.R. 75), H100 [9JA]

——— repeal guidance to require veterinary oversight for use of medically important antimicrobial animal drugs available as over-the-counter products (see H.R. 4012), H2807 [12JN]

——— require label of drug intended for human use to identify each ingredient that is, or is derived directly or indirectly from, major food allergen or gluten-containing grain (see S. 2079), S2185 [21JN] (see H.R. 4263), H3071 [21JN]

——— require manufacturers of life-saving drugs to submit data and information to assess stability of such drugs and determine their longest supported expiration date (see H.R. 3793), H2740 [5JN]

——— require more accurate reporting of abortion drug prescribing and related adverse events (see H.R. 2570), H1717 [10AP]

——— require research on fentanyl and xylazine test strips and authorize use of grant funds for such test strips (see S. 2919), S4678 [26SE]

——— respect scientific judgement that mifepristone is safe and effective and ensure access to lifesaving, time-sensitive medication abortion care in U.S. is equitable and based on science (see S. Res. 510), S5997 [14DE]

——— revoke approval of one opioid pain medication for each new opioid pain medication approved (see S. 606), S568 [1MR]

——— set forth limitations on exclusive approval or licensure of drugs designated for rare diseases or conditions (see S. 1214), S1256 [19AP]

——— strengthen authority relative to foreign drug facility inspections (see S. 1134), S1090 [30MR]

——— strengthen use of patient-experience data within benefit-risk framework for approval of new drugs (see S. 526), S457 [16FE] (see H.R. 1092), H853 [17FE]

FDA and Office of the U.S. Trade Representative: require reports on and investments in pharmaceutical supply chain resiliency to reduce reliance on China for finished pharmaceutical products and active pharmaceutical ingredients (see S. 2454), S3459 [20JY]

Federal agencies and departments: limit consideration of marijuana use when making security clearance or employment suitability determination (see H.R. 5040), H4140 [27JY]

——— prohibit from imposing any mandate requiring individuals to receive vaccine that has not been authorized for marketing for at least 10 years (see H.R. 2631), H1758 [17AP]

——— provide for greater accountability relative to Federal activities and expenditures relating to coronavirus (see H.R. 271), H202 [11JA]

Federal aid programs: ensure equitable treatment of covered entities and pharmacies participating in 340B drug discount program (see H.R. 2534), H1709 [6AP]

——— increase reporting and transparency requirements in 340B Drug Pricing Program (see S. 1182), S1210 [18AP] (see H.R. 198), H105 [9JA]

——— reauthorize program to support individuals in substance use disorder treatment and recovery to live independently and participate in workforce (see H.R. 4088), H2930 [14JN]

——— recognize essential benefit of Medicare and Social Security programs to current enrollees and strengthen such programs for future generations (see H. Res. 73), H510 [30JA]

Federal employees: provide for reinstatement or compensation of Federal employees forced to resign due to coronavirus vaccination mandate (see H.R. 1080), H852 [17FE]

Federal-State relations: prohibit use of Federal funds to prevent States from implementing their own laws relative to psilocybin (see H.R. 5592), H4436 [20SE]

——— withold certain Federal highway funds from jurisdictions that permit recreational use of marijuana (see H.R. 5323), H4217 [1SE]

FEMA: authorize President to expand Crisis Counseling Assistance and Training Program to provide victims of natural disaster with substance use and alcohol use disorder services (see H.R. 5623), H4454 [21SE]

Fentanyl Prevention and Awareness Day: support goals and ideals (see S. Res. 323), S3758 [27JY]

Financial institutions: create protections for depository institutions that provide financial services to legitimate marijuana-related businesses (see H.R. 2891), H2047 [26AP]

——— create protections for financial institutions that provide financial services to State-sanctioned marijuana businesses and service providers for such businesses (see S. 1323), S1382 [26AP] (see S. 2860), S4630 [20SE]

Firearms: amend laws relative to sale, purchase, shipment, receipt, or possession of firearm or ammunition by user of medical marijuana (see H.R. 363), H238 [13JA]

——— protect rights of persons whose use of marijuana is permitted by State or Tribal law to own firearms (see H.R. 2772), H1908 [20AP]

Foreign countries: disrupt international fentanyl supply chain (see H.R. 3205), H2307 [11MY]

——— strengthen imposition of sanctions on associates and facilitators of fentanyl traffickers (see H.R. 6505), H5982 [29NO]

Foreign trade: require reciprocity with respect to de minimis entries of articles (see S. 1969), S2096 [14JN]

Forest Service: use Superfund toxic waste remediation funds to address environmental damages caused by trespass cannabis cultivation and increase criminal penalties for use of illegal pesticides on Federal lands (see H.R. 1473), H1206 [8MR]

Freedom of religion: prohibit imposition of certain substantial burdens relative to coronavirus vaccine mandates on religious exercise (see S. 492), S456 [16FE]

FTC: deter filing of sham citizen petitions to cover attempt to interfere with approval of competing generic drug or biosimilar and foster competition and facilitate review of drug petitions filed in good faith (see S. 148), S147 [30JA]

——— prevent unfair and deceptive acts or practices and dissemination of false information relative to pharmacy benefit management services for prescription drugs (see S. 127), S121 [26JA]

——— prohibit anticompetitive use of patents, known as product hopping, by drug product manufacturers (see S. 150), S147 [30JA]

——— study role of intermediaries in pharmaceutical supply chain and merger activity and provide Congress with appropriate policy recommendations (see S. 113), S121 [26JA]

GAO: conduct review examining Dept. of HHS efforts to ensure that U.S. is prepared to rapidly produce certain medical countermeasures in public health emergency (see H.R. 3703), H2637 [25MY]

——— conduct review on impact of crime on public building usage (see H.R. 6261), H5543 [7NO]

——— conduct study and submit report on price-related compensation and payment structures in prescription drug supply chain (see S. 2198), S2224 [22JN]

——— conduct study on naloxone access (see H.R. 4005), H2807 [12JN]

——— require report on effects of fentanyl crisis (see H.R. 5237), H4191 [18AU]

——— study accessibility of substance use disorder treatment and mental health care providers and services for farmers and ranchers (see S. 3206), S5338 [2NO]

——— study and report on efficacy of Federal drug surveillance systems (see H.R. 6045), H5103 [25OC]

——— study sale of illicit drugs online (see S. 2982), S4759 [28SE]

——— study trafficking of synthetic drugs into U.S. and related illicit finance (see S. 2227), S2310 [11JY] (see H.R. 1076), H852 [17FE]

Government regulations: allow sponsors of certain new drug applications to rely on investigations conducted in certain foreign countries (see S. 1132), S1090 [30MR]

——— provide for congressional review of rules rescheduling marijuana (see S. 2909), S4654 [21SE]

Haiti: call for diplomatic efforts by U.S. and international partners to achieve negotiated, Haitian-led solution leading to representative interim government and return to constitutional rule through free and fair elections (see H. Res. 471), H2763 [6JN]

Harris, Vice President: impeachment (see H. Res. 494), H2809 [12JN]

——— remove from position as head of Biden administration strategy to address root causes of migration (see H. Res. 253), H1438 [24MR]

Health: address prescription drug shortages and improve quality of prescription drugs (see S. 2586), S3753 [27JY]

——— allow for use of telehealth in substance use disorder treatment (see S. 3193), S5315 [1NO] (see H.R. 5163), H4165 [4AU]

——— amend laws relative to registration of opioid treatment programs to increase stakeholder input from relevant communities and ensure such programs are treating patients in need (see H.R. 2804), H1914 [24AP]

——— exempt sunscreen from over-the-counter medication bans in schools, encourage community and youth-related entities to provide access to sunscreen and sun-protective clothing, and teach sun-safe behaviors (see H. Res. 365), H2136 [5MY]

——— express that fentanyl-related substances are a weapon of mass destruction and should be classified as such (see H. Res. 39), H243 [17JA]

——— extend Federal support for bioindustrial manufacturing processes to include support for manufacturing of certain pharmaceutical ingredients (see H.R. 6895), H7006 [22DE]

——— fund detection and testing activities, such as wastewater surveillance, to detect synthetic opioids (see H.R. 4773), H3886 [20JY]

——— prohibit consideration of coronavirus vaccination status in determining eligibility for organ donation or transplantation and in providing services to Medicare or Medicaid beneficiaries (see S. 164), S172 [31JA]

——— prohibit consideration of race, color, religion, sex, national origin, age, disability, vaccination status, veteran status, political ideology, or speech in determining eligibility for coronavirus treatments and vaccines (see S. 171), S172 [31JA]

——— prohibit Federal funds from being made available to entities that refuse to provide treatment based on coronavirus vaccination status (see S. 420), S397 [14FE] (see H.R. 991), H837 [14FE]

——— protect individual liberty, ensure privacy, and prohibit discrimination relative to coronavirus vaccination status of individuals (see S. 181), S172 [31JA]

——— review and improve domestic biopharmaceutical manufacturing capabilities and public health and medical preparedness and response (see S. 36), S74 [24JA]

Health care facilities: expand take-home prescribing of methadone through pharmacies (see S. 644), S636 [2MR] (see H.R. 1359), H1113 [3MR]

Health care professionals: clarify training requirements for prescribers of controlled substances (see S. 3550), S5996 [14DE]

Health Resources and Services Administration: modify loan repayment program for substance use disorder treatment workforce to relieve workforce shortages (see S. 462), S455 [16FE] (see H.R. 4933), H4029 [26JY]

——— reauthorize loan repayment program for substance use disorder treatment workforce (see S. 3200), S5338 [2NO] (see H.R. 3355), H2375 [16MY] (see H.R. 4079), H2884 [13JN]

Immigration: establish certain funds to construct and maintain physical barriers along southern U.S. border and award grants to certain organizations addressing fentanyl crisis (see H.R. 4904), H4028 [26JY]

——— prohibit individuals charged with or convicted of human trafficking or drug trafficking offenses committed near border from receiving Federal benefits (see S. 519), S457 [16FE] (see H.R. 1116), H864 [21FE]

——— recognize current influx of migrants is causing crisis at U.S. Southern border (see S. Res. 45), S313 [9FE]

——— recognize State sovereign power to repel invasion and defend citizenry from overwhelming and imminent danger posed by paramilitary, narco-terrorist cartels at southern border (see H. Res. 50), H251 [20JA]

——— secure U.S. borders and reform immigration policies (see S. 2824), S4526 [14SE] (see H.R. 2), H2124 [2MY]

——— secure U.S. borders and reform immigration policies (H.R. 2), call on President to sign (see H. Con. Res. 53), H3071 [21JN]

——— secure U.S. borders and reform immigration policies (H.R. 2), consideration (see H. Res. 383), H2243 [10MY]

——— terminate requirement for proof of coronavirus vaccination for aliens (see H.R. 4726), H3856 [19JY]

Income: establish incentive pay for positions requiring specialized skills to combat fentanyl trafficking (see S. 1175), S1210 [18AP]

Inflation Reduction Act: repeal (see H.R. 812), H678 [2FE]

——— repeal Medicare prescription drug price control provisions (see S. 2157), S2223 [22JN]

Information technology: prohibit delivery of opioids by means of dark web (see S. 1728), S1744 [18MY] (see H.R. 3587), H2500 [22MY]

——— remove immunity protections for online platforms related to certain laws regarding controlled substances and drugs (see H.R. 4910), H4028 [26JY]

Infrastructure Investment and Jobs Act: repeal provision relative to advanced impaired driving technology motor vehicle safety standard (see H.R. 6563), H6080 [1DE]

Insulin: limit price charged by manufacturers for insulin (see S. 727), S742 [9MR] (see H.R. 1485), H1247 [9MR]

——— reduce price for patients (see S. 146), S147 [30JA]

——— reduce price of insulin, require pharmacy benefit managers to pass-through manufacturer rebates for insulin products, and promote generic and biosimilar competition (see S. 1269), S1340 [25AP]

Insurance: apply additional payments, discounts, and other financial assistance towards cost-sharing requirements of health insurance plans (see S. 1375), S1419 [27AP] (see H.R. 830), H708 [6FE]

——— ban anticompetitive terms in facility and insurance contracts that limit access to higher quality, lower cost care (see S. 1451), S1533 [4MY] (see H.R. 3120), H2135 [5MY]

——— establish requirements relative to cost-sharing for certain insulin products (see H.R. 1488), H1247 [9MR]

——— increase oversight of pharmacy benefits manager services (see S. 2694), S3756 [27JY] (see H.R. 2679), H1845 [18AP] (see H.R. 4846), H3948 [25JY]

——— limit cost-sharing for prescription drugs (see H.R. 6347), H5668 [9NO]

——— provide for increased oversight of entities that provide pharmacy benefit management services on behalf of group health plans and health insurance coverage (see S. 1339), S1417 [27AP] (see H.R. 4507), H3176 [10JY] (see H.R. 4712), H3699 [18JY]

——— require group health plans and group or individual health insurance coverage to provide coverage for over-the-counter contraceptives (see S. 1698), S1743 [18MY] (see H.R. 3589), H2500 [22MY]

——— require group health plans to provide exceptions process for any medication step therapy protocol (see S. 652), S636 [2MR] (see H.R. 2630), H1725 [13AP]

——— require health insurance providers to cover oral cancer drugs on terms no less favorable than for cancer medications administered by health care provider (see S. 2039), S2123 [15JN] (see H.R. 6301), H5651 [8NO]

——— require out-of-network coverage for qualified individuals diagnosed with rare pediatric disease participating in approved clinical trials (see H.R. 5647), H4455 [21SE]

——— strengthen transparency requirements relative to pharmacy benefit managers (see H.R. 2816), H1945 [25AP]

Interstate commerce: authorize regulation relative to food containing cannabidiol derived from hemp (see H.R. 1628), H1292 [17MR]

IRS: transfer certain unobligated balances of amounts made available under Inflation Reduction Act to Dept. of Homeland Security to secure southern border (see H.R. 4230), H3069 [21JN]

Law enforcement: clarify possession, sale, purchase, importation, exportation, or transportation of drug testing equipment that tests for presence of fentanyl or xylazine is not unlawful (see S. 2569), S3753 [27JY]

——— codify penalty for selling, giving, or distribution of fentanyl and fentanyl-related substances (see H.R. 1597), H1285 [14MR]

——— focus limited Federal resources on most serious offenders by modifying sentencing guidelines for certain drug offenses (see S. 1152), S1091 [30MR]

——— prohibit certain uses of xylazine (see S. 993), S999 [28MR] (see H.R. 1839), H1527 [28MR]

——— provide enhanced capabilities to combat transnational criminal cartels (see H.R. 713), H627 [1FE]

——— provide first-time, low-level, nonviolent simple drug possession offenders opportunity to expunge conviction after successful completion of court-imposed probation (see S. 2596), S3754 [27JY] (see H.R. 4958), H4136 [27JY]

——— provide for requirements for electronic-prescribing for controlled substances under group health plans and group and individual health insurance coverage (see S. 2666), S3756 [27JY]

——— reform sentencing laws and correctional institutions (see S. 1251), S1294 [20AP]

——— use forfeited criminal proceeds resulting from prosecution of Joaquín A. Guzmán Loera (El Chapo) or other felony drug convictions for border security measures, including border wall (see H.R. 1793), H1437 [24MR]

Marijuana: create safe harbor for insurers engaging in business of insurance in connection with cannabis-related business (see S. 1359), S1418 [27AP] (see H.R. 2984), H2085 [27AP]

——— decriminalize, expunge prior convictions, tax products to create programs for those adversely affected by War on Drugs, and provide assistance and collect data on small businesses (see H.R. 5601), H4437 [20SE]

——— provide for new rules on regulation of marijuana (see H.R. 6673), H6740 [7DE]

——— remove cannabis from schedule I under Controlled Substances Act to allow States to determine their own level of cannabis reform (see H.R. 6028), H5042 [24OC]

——— reschedule marijuana under Controlled Substances Act (see H.R. 610), H489 [27JA]

Mayorkas, Sec. of Homeland Security: condemn for failure to secure U.S. southern border (see S. Res. 169), S1294 [20AP]

Medicaid: codify value-based purchasing arrangements and reforms relative to price reporting under such arrangements (see H.R. 2666), H1844 [18AP]

——— encourage appropriate prescribing for victims of opioid overdose (see S. 2481), S3522 [25JY] (see H.R. 4950), H4030 [26JY]

——— ensure that medical assistance is available to children in foster care who are placed in qualified residential treatment program (see H.R. 4056), H2883 [13JN]

——— expand programs to monitor antipsychotic medications to all beneficiaries (see H.R. 4096), H2930 [14JN]

——— expand required reports on Transformed Medicaid Statistical Information System (T-MSIS) substance use disorder data to include mental health condition data (see H.R. 4091), H2930 [14JN]

——— improve transparency and prevent use of abusive spread pricing and related practices (see S. 1038), S1052 [29MR] (see H.R. 1613), H1292 [17MR]

——— provide higher Federal matching rate for increased expenditures for behavioral health services, including those related to mental health and substance use (see H.R. 4892), H3950 [25JY]

——— provide State option to extend coverage for foster care children while receiving treatment from qualified residential treatment program (see S. 3196), S5315 [1NO]

Medicare: amend timing of changes to annual out-of-pocket threshold for prescription drug benefit and timing of drug price negotiation program (see H.R. 5924), H4998 [11OC]

——— apply prescription drug inflation rebates to drugs furnished in commercial market and change base year for rebate calculations (see S. 1139), S1090 [30MR] (see H.R. 4115), H2931 [14JN]

——— assure pharmacy access and choice for beneficiaries (see S. 2405), S3458 (see S. 2436), S3459 [20JY] (see H.R. 5400), H4262 [12SE]

——— clarify application of in-office ancillary services exception to physician self-referral prohibition for drugs (see S. 3458), S5897 [11DE] (see H.R. 5526), H4379 [18SE]

——— clarify congressional intent and preserve patient access to home infusion therapy (see S. 1976), S2096 [14JN] (see H.R. 4104), H2930 [14JN]

——— coordinate programs to prevent and treat obesity (see S. 2407), S3458 [20JY] (see H.R. 4818), H3888 [20JY]

——— delay implementation of inclusion of oral-only End-Stage Renal Disease (ESRD) related drugs in End-Stage Renal Disease prospective payment system (see H.R. 5074), H4151 [28JY]

——— enforce any willing pharmacy requirements and establish safeguards to ensure patient access to pharmacies in part D (see S. 2052), S2145 [20JN]

——— ensure appropriate cost-sharing for chronic care drugs under part D (see S. 2474), S3521 [25JY] (see H.R. 5376), H4229 [8SE]

——— ensure equitable payment for, and beneficiary access to, diagnostic radiopharmaceuticals under hospital outpatient prospective payment system (see S. 1544), S1603 [10MY] (see H.R. 1199), H914 [27FE]

——— ensure fair assessment of pharmacy performance and quality under part D (see H.R. 5393), H4262 [12SE]

——— ensure Medicare-only PACE program enrollees have choice of prescription drug plans under part D (see S. 1703), S1743 [18MY] (see H.R. 3549), H2456 [18MY]

——— establish cap on costs for covered prescription drugs (see S. 1450), S1533 [4MY]

——— establish certain standards for pharmacy benefit managers under prescription drug program (see H.R. 2880), H2047 [26AP]

——— establish demonstration project to increase access to biosimilar biological products (see H.R. 1352), H1112 [3MR]

——— establish improved Medicare for All national health insurance program (see S. 1655), S1704 [17MY] (see H.R. 3421), H2424 [17MY]

——— establish pharmacy benefit manager reporting requirements relative to prescription drug plans and Medicare Advantage prescription drug plans (see S. 2254), S2359 [12JY] (see H.R. 5385), H4262 [12SE]

——— establish requirements relating to responsibility of pharmacy benefit managers under part D (see S. 1967), S2096 [14JN]

——— expand eligibility for incentives under health professional shortage area bonus program to practitioners furnishing mental health and substance use disorder services (S. 5042) (see S. 3157), S5213 [26OC]

——— extend eligibility for certain payment increases for biosimilar biological products (see H.R. 6400), H5855 [14NO]

——— facilitate midyear formulary changes for biosimilars (see H.R. 5372), H4229 [8SE]

——— improve access to opioid use disorder treatment services (see S. 3326), S5540 [15NO]

——— improve oversight of formulary development and management under part D (see S. 2406), S3458 [20JY]

——— limit beneficiary cost-sharing to net price of covered part D drugs (see S. 2456), S3459 [20JY]

——— make premium and cost-sharing subsidies available to low-income part D beneficiaries residing in Puerto Rico or other U.S. territories (see H.R. 4028), H2807 [12JN]

——— prohibit Dept. of HHS from entering into contracts with sponsors of prescription drug plans that have contract with certain pharmacy benefits managers (see H.R. 6844), H6992 [15DE]

——— promote access to opioid treatments and require coverage of medication assisted treatment, overdose reversal medications, and recovery support services by health plans without cost-sharing requirements (see S. 818), S798 [15MR] (see H.R. 1620), H1292 [17MR]

——— promote transparency of common ownership interests under parts C and D (see H.R. 3282), H2342 [15MY]

——— provide coverage of external infusion pumps and non-self-administrable home infusion drugs (see H.R. 5397), H4262 [12SE]

——— provide coverage of pharmacist-administered tests, treatments, and vaccinations (see S. 2477), S3522 [25JY]

——— provide for adjustments to part D cost-sharing reductions for low-income individuals (see H.R. 5386), H4262 [12SE]

——— provide for automatic qualification of certain Medicaid beneficiaries for premium and cost-sharing subsidies under part D (see H.R. 5384), H4262 [12SE]

——— provide for certain rules on treatment of eligible retirement plans in determining eligibility of individuals for premium and cost-sharing subsidies under part D (see H.R. 2893), H2048 [26AP]

——— provide for coverage of certain pharmacist services in underserved areas (see S. 1491), S1566 [9MY]

——— provide for patient-focused listening sessions to improve prescription drug plan transparency, access, and choice (see S. 2408), S3458 [20JY]

——— provide for rebate by manufacturers for selected drugs and biological products subject to maximum fair price negotiation (see S. 2764), S4388 [12SE] (see H.R. 5391), H4262 [12SE]

——— provide for transparency of funds appropriated for purposes of implementing price negotiation program to lower prices for certain high-priced single source drugs (see S. 1589), S1624 [11MY]

——— provide incentives for behavioral health integration (see S. 1378), S1419 [27AP] (see H.R. 5819), H4855 [28SE]

——— provide phase-in for plasma-derived products under manufacturer discount program (see H.R. 6465), H5902 [21NO]

——— provide review process for adverse national coverage determinations relative to drug coverage of certain new, innovative treatments (see H.R. 2408), H1690 [30MR]

——— require complete and accurate data submissions from Medicare Advantage organizations offering plans under Part C to improve transparency (see H.R. 5854), H4910 [29SE]

——— require Medicare Payment Advisory Commission submit reports to Congress on arrangements with pharmacy benefit managers relative to prescription drug plans and Medicare Advantage prescription drug plans (see S. 2493), S3522 [25JY]

——— require reporting on enforcement and oversight of pharmacy access requirements under part D (see S. 2939), S4720 [27SE]

——— require sponsors of prescription drug plans and Medicare Advantage organizations offering such plans under part D to include certain drugs and biosimilar biological products on formulary (see S. 2129), S2222 [22JN] (see H.R. 5461), H4344 [14SE]

——— strengthen certain drug pricing reforms (see S. 1246), S1293 [20AP] (see S. 1264), S1340 [25AP]

Medicare/Medicaid: establish requirements relating to pharmacy benefit managers (see S. 2973), S4759 [28SE]

——— expand mental health care workforce and services, reduce prescription drug costs, and extend certain expiring provisions (see S. 3430), S5851 [7DE]

——— provide coverage of prescription digital therapeutics for treatment of mental health and substance use disorders (see S. 723), S715 [8MR] (see H.R. 1458), H1205 [8MR]

——— provide no-cost coverage for preventive distribution of opioid overdose reversal drugs (see H.R. 5506), H4345 [14SE]

——— refine set of information sources for determining coverage of certain drugs and biologicals used in treatment or management of rare disease or condition (see H.R. 6094), H5173 [26OC]

——— reform and improve mental health and substance use care (see S. 923), S909 [22MR]

——— require drug and biological product manufacturers to include truthful and non-misleading pricing information in any direct-to-consumer advertising (see S. 1250), S1294 [20AP] (see H.R. 5958), H5013 [13OC]

Mental health: extend task force to develop best practices for trauma-informed identification, referral, and support (see H.R. 4080), H2884 [13JN]

Mexico: express concern about economic and security conditions and reaffirm interest in mutually beneficial relations based on shared interests on security, economic prosperity, and democratic values (see S. Res. 97), S715 [8MR]

——— limit availability of certain funds for Mexico until President makes certification to Congress regarding cooperation by Mexico with respect to fentanyl (see H.R. 3190), H2244 [10MY]

——— reaffirm U.S. commitment to respecting sovereignty and condemn calls for military action in Mexico without Mexico’s consent and congressional authorization (see H. Res. 763), H4990 [6OC]

Middle East: enhance region’s capacity to dismantle and disrupt illicit production and trafficking of amphetamine-type stimulant also known as captagon, including production of precursor chemicals (see H. Res. 836), H5229 [1NO]

National Adult Hepatitis B Vaccination Awareness Day: designate (see S. Res. 180), S1419 [27AP] (see H. Res. 338), H2118 [28AP]

National Fentanyl Awareness Day: designate (see S. Res. 215), S1705 [17MY] (see H. Res. 381), H2172 [9MY]

National Fentanyl Awareness Week: designate (see S. Res. 79), S507 [27FE]

National Naloxone Awareness Day: designate (see S. Res. 250), S2071 [13JN] (see H. Res. 476), H2763 [6JN]

National Recovery Month: designate (see H. Res. 729), H4499 [26SE]

NIH: conduct or support further comprehensive research for creation of universal influenza vaccine (see S. 3215), S5338 [2NO] (see H.R. 6184), H5362 [2NO]

——— make awards to outstanding scientists, including physician-scientists, to support researchers focusing on pediatric research, including basic, clinical, translational, or pediatric pharmacological research (see S. 2345), S2984 [18JY] (see H.R. 4714), H3699 [18JY]

——— take certain steps to increase clinical trial diversity (see S. 1701), S1743 [18MY] (see H.R. 3503), H2454 [18MY]

——— transfer pharmaceutical civil penalties to Gabriella Miller Kids First Pediatric Research Program Fund (see S. 1624), S1678 [16MY]

NIST: coordinate science and research activities relative to illicit drugs containing xylazine, novel synthetic opioids, and other substances of concern (see S. 1280), S1340 [25AP] (see H.R. 1734), H1407 [23MR]

Office of National Drug Control Policy: require Caribbean border counternarcotics strategy (see S. 309), S310 [9FE] (see H.R. 920), H823 [9FE]

Patents: establish interagency task force between Patent and Trademark Office and FDA for sharing information and providing technical assistance relative to patents (see S. 79), S98 [25JA] (see H.R. 1717), H1326 [22MR]

——— require sponsors of drug applications and holders of approved applications to provide certain submissions and communications to FDA and Patent and Trademark Office (see S. 2780), S4440 [13SE] (see H.R. 5429), H4296 [13SE]

Patient Protection and Affordable Care Act: ensure taxpayer funds for health insurance coverage are available only to authorized individuals (see H.R. 5875), H4985 [3OC]

Pharmaceuticals: clarify Federal Right To Try laws apply to schedule 1 substances for which phase 1 clinical trial has been completed and provide access to eligible patients to such substances (see H.R. 1825), H1526 [28MR]

——— clarify that artificial intelligence and machine learning technologies can qualify as practitioner eligible to prescribe drugs if State authorized and FDA approved, cleared, or authorized (see H.R. 206), H105 [9JA]

——— encourage innovation in development of pediatric drugs and ensure drugs for rare diseases are studied in children and drug companies are accountable for completing pediatric study requirements (see H.R. 6664), H6739 [7DE]

——— end dependence on Chinese pharmaceuticals by encouraging growth of robust domestic medicine supply chain for generic drugs and empower FDA to issue warnings for critical contaminations (see H.R. 5575), H4407 [19SE]

——— improve actions available to eligible product developers in event of delays in receiving covered product for purposes of generic drug or biosimilar biological product development (see S. 1120), S1090 [30MR]

——— improve services provided by pharmacy benefit managers (see S. 1542), S1603 [10MY] (see H.R. 6283), H5650 [8NO]

——— increase transparency of research costs (see S. 1476), S1566 [9MY] (see H.R. 3160), H2171 [9MY]

——— map U.S. pharmaceutical supply chain and use data analytics to identify supply chain vulnerabilities and other national security threats (see S. 2364), S2985 [18JY]

——— prohibit prescription drug manufacturers from compensating other companies to delay entry of generic drugs, biosimilar biological products, or interchangeable biological products into market (see S. 142), S147 [30JA] (see H.R. 6275), H5544 [7NO]

——— prohibit use of patents, trade secrets, or other intellectual property to inhibit competition (see S. 574), S567 [1MR] (see H.R. 4692), H3640 [17JY]

——— require interagency risk assessment of pharmaceutical supply chain to identify and mitigate health and national security risks (see S. 1961), S2071 [13JN]

——— require regulations concerning disclosure of direct and indirect compensation from entities providing pharmacy benefit management services or third party administration services (see S. 1543), S1603 [10MY]

——— study effects of remote monitoring on individuals who are prescribed opioids (see H.R. 4093), H2930 [14JN]

Postal Service: increase criminal penalty for mail fraud involving misrepresentation of country of origin and terminate authority to exclude countries from requirement to transmit advance electronic information for all shipments (see S. 986), S954 [27MR]

Prematurity Research Expansion and Education for Mothers Who Deliver Infants Early (PREEMIE) Act: reauthorize (see S. 1573), S1624 [11MY] (see H.R. 3226), H2308 [11MY]

Privacy: prohibit use of Federal funds to maintain or collect information that can be used to identify any individual to whom coronavirus vaccine is administered (see H.R. 72), H100 [9JA]

Public welfare programs: require certain programs to deny benefits to persons who fail drug test (see H.R. 204), H105 [9JA]

Puerto Rico: improve collection and publication of statistics (see H.R. 258), H150 [10JA]

Rare Disease Day: designate (see H. Res. 181), H970 [28FE]

Red Ribbon Week: support goals and ideals (see S. Res. 383), S4760 [28SE] (see S. Res. 449), S5339 [2NO] (see H. Res. 747), H4910 [29SE]

Safety: ensure that States do not prohibit individuals from obtaining, possessing, distributing, or using life-saving drug testing technologies (see S. 2484), S3522 [25JY]

Schools: authorize grants to implement school-community partnerships for preventing substance use and misuse among youth (see H.R. 5975), H5020 [17OC]

——— require that opioid overdose rescue kits be located at public elementary and secondary schools (see H.R. 4240), H3070 [21JN]

Secret Service: require report on illicit use of controlled substances at Executive Residence (see H.R. 5200), H4181 [11AU]

Senate: prohibit imposition of vaccination, testing, and masking requirements relative to coronavirus for Senate Pages (see S. Res. 332), S4270 [7SE]

——— prohibit imposition of vaccination requirements relative to coronavirus for Senate Pages (see S. Res. 336), S4389 [12SE]

Social Security: clarify manufacturer transparency reporting requirements for certain transfers used for educational purposes (see H.R. 4402), H3157 [30JN]

——— provide mental health and substance use services to incarcerated individuals under Medicaid and State Children’s Health Insurance Program (see S. 3451), S5851 [7DE] (see H.R. 6675), H6740 [7DE]

——— reform (see H.R. 671), H575 [31JA]

Sports: protect health and welfare of horses and improve integrity and safety of horseracing by authorizing States to enter into interstate compact to develop and enforce scientific medication control and racetrack safety rules (see H.R. 5693), H4497 [26SE]

Substance Abuse and Mental Health Services Administration: authorize use of certain grants for health care providers to purchase lethal-means safety supplies for children at risk of suicide or overdose (see S. 3364), S5692 [30NO] (see H.R. 6663), H6739 [7DE]

——— award grants to States to expand access to clinically appropriate services for opioid abuse, dependence, or addiction (see H.R. 3412), H2424 [17MY]

——— limit funding for substance abuse prevention (see H.R. 2004), H1627 [29MR]

——— limit funding for substance abuse treatment (see H.R. 2003), H1627 [29MR]

——— reauthorize grants for building communities of recovery (see H.R. 4098), H2930 [14JN]

——— reauthorize National Peer-Run Training and Technical Assistance Center for Addiction Recovery Support (see H.R. 4101), H2930 [14JN]

——— reauthorize residential treatment program for pregnant and postpartum women (see S. 3447), S5851 [7DE]

Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act: reauthorize (see S. 3393), S5712 [4DE]

——— reauthorize certain programs (see S. 2433), S3459 [20JY] (see S. 3106), S5143 [24OC]

——— reauthorize youth prevention and recovery initiative (see S. 3070), S5087 [18OC] (see H.R. 5598), H4437 [20SE]

Tardive Dyskinesia Awareness Week: designate (see S. Res. 197), S1534 [4MY] (see H. Res. 367), H2136 [5MY]

Taxation: allow deductions and credits relating to expenditures in connection with marijuana sales conducted in compliance with State law (see H.R. 2643), H1758 [17AP]

——— establish excise tax on production and importation of opioid pain relievers and use such funds to provide and expand access to substance abuse treatment (see S. 2559), S3752 [27JY]

——— establish generic drugs and biosimilars production credit (see H.R. 6109), H5174 [26OC]

——— include amounts paid for over-the-counter naloxone to qualify for medical expenses deduction (see H.R. 6161), H5228 [1NO]

——— include certain over-the-counter dietary supplements and foods for special dietary uses as qualified medical expenses (see S. 3172), S5257 [31OC]

——— permit expenditures from health savings accounts, flexible spending arrangements, and health reimbursement arrangements for dietary supplements (see H.R. 4794), H3887 [20JY]

——— provide authority to add additional vaccines to list of taxable vaccines (see H.R. 5143), H4164 [4AU]

——— restore amount of orphan drug tax credit (see H.R. 1350), H1112 [3MR]

Temporary Reauthorization and Study of the Emergency Scheduling of Fentanyl Analogues Act: extend (see S. 1950), S2071 [13JN]

Travel and tourism: prohibit Federal Government from mandating coronavirus vaccination for interstate travel (see S. 899), S860 [21MR]

Venezuela: reauthorize initiatives to provide humanitarian relief, advance solution to political crisis, address economic reconstruction, and combat public corruption, narcotics trafficking, and money laundering (see H.R. 6831), H6985 [14DE]

Veterans: ensure servicemembers granted general discharge under honorable conditions on sole basis of failure to obey lawful order to receive coronavirus vaccine is eligible for certain educational assistance (see H.R. 291), H203 [11JA]

Western Hemisphere Drug Policy Commission: limit funding for salaries and expenses (see H.R. 2330), H1638 [29MR]

World Hepatitis Day: observance (see H. Res. 632), H4142 [27JY]

Cloture motions

Dept. of Veterans Affairs: carry out clinical trial of effects of cannabis on certain health outcomes of adults with chronic pain and post-traumatic stress disorder (S. 326), motion to proceed, S1286 [20AP], S1360 [26AP]

Letters

Animal Drug User Fee Act reauthorization performance goals and procedures fiscal year 2024 through 2028: FDA, S5038–S5042 [17OC]

Animal Generic User Fee Act reauthorization performance goals and procedures fiscal year 2024 through 2028: FDA, S5042 [17OC]

Freedom for Health Care Workers Act: several Representatives, H539 [31JA]

Secure the Border Act: Donna Markham, Catholic Charities USA, H2231 [10MY]

——— Mark J. Seitz, U.S. Conference of Catholic Bishops, H2232 [10MY]

——— Rebecca Wasserman, Service Employees International Union, H2229 [10MY]

——— Representative Jason Smith, Committee on Ways and Means (House), H2217 [10MY]

——— Representative Jordan, Committee on the Judiciary (House), H2217 [10MY]

——— Representative Mark E. Green, Committee on Homeland Security (House), H2217, H2218 [10MY]

——— several organizations, H2229, H2230 [10MY]

——— Ted Penton, Jesuit Conference (organization), H2233 [10MY]

——— William Samuel, AFL–CIO, H2228 [10MY]

Stop Chinese Fentanyl Act: Representative Jordan, Committee on the Judiciary (House), H3912 [25JY]

——— Representative McCaul, Committee on Foreign Affairs (House), H3912 [25JY]

——— Representative McHenry, Committee on Financial Services (House), H3912 [25JY]

Messages

Authority To Order Ready Reserve of Armed Forces to Active Duty To Address International Drug Trafficking: President Biden, S1416 [27AP], H2069 [27AP]

Budget of the U.S. Government for Fiscal Year 2024: President Biden, S996 [28MR], H1516 [28MR]

National Emergency Relative to Global Illicit Drug Trade: President Biden, S5958 [13DE], H6926 [13DE]

National Emergency Relative to Narcotics Traffickers in Colombia: President Biden, S5046 [17OC], H5065 [25OC]

Motions

CDC: terminate requirement for proof of coronavirus vaccination for foreign travelers (H.R. 185), H760 [8FE]

Dept. of Veterans Affairs: carry out clinical trial of effects of cannabis on certain health outcomes of adults with chronic pain and post-traumatic stress disorder (S. 326), S1285 [20AP]

Diseases and disorders: eliminate coronavirus vaccine mandate on health care providers furnishing items and services under certain Federal health care programs (H.R. 497), H548 [31JA]

Immigration: secure U.S. borders and reform immigration policies (H.R. 2), H2281 [11MY]

Notices

Intention to object to proceeding to S. 1080, require electronic communication service providers and remote computing services to report unlawful sale and distribution of controlled substances to Dept. of Justice: Senator Wyden, S3500 [20JY]

Remarks in House

Abortion: ensure that women seeking chemical abortions are informed that it may be possible to reverse intended effects of abortion if they change their mind (H.R. 983), H270 [24JA]

——— Texas Federal district court decision in Alliance for Hippocratic Medicine v. FDA relative to approval of abortion pill mifepristone, H1743 [17AP], H1768, H1790 [18AP], H1874 [19AP], H1889, H1896, H1898 [20AP]

——— Texas Federal district court hearing of Alliance for Hippocratic Medicine v. FDA relative to approval of abortion pill mifepristone, H1236 [9MR]

Adult and Teen Challenge (organization): tribute, H924 [28FE]

American Pharmacists Month: observance, H5154 [26OC]

Armed Forces: provide remedies to members discharged or subject to adverse action under coronavirus vaccine mandate, H3219 [12JY]

Armstrong-Indiana-Clarion Drug and Alcohol Commission: National Liquor Law Enforcement Association John W. Britt Community Service Award recipient, H899 [27FE]

Biden, President: evaluation of administration, H777–H780 [8FE], H3065–H3068 [21JN], H3193 [11JY], H5883–H5888 [15NO]

——— evaluation of administration relative to fentanyl and opioid epidemic, H2586 [24MY]

——— evaluation of administration relative to foreign policy, H5463 [6NO]

——— evaluation of administration relative to immigration, H97 [9JA], H117, H146 [10JA], H165 [11JA], H229 [12JA], H292, H319 [25JA], H340, H341, H343, H346, H350, H422 [26JA], H482 [27JA], H634, H653, H664 [2FE], H807 [9FE], H1198 [8MR], H1214 [9MR], H1268, H1274, H1277 [10MR], H1688 [30MR], H1795–H1797 [18AP], H2141 [9MY], H2222 [10MY], H2553, H2587 [24MY], H2970 [20JN], H3077–H3088 [22JN], H3130 [23JN], H3212 [12JY], H3615 [17JY], H3645, H3646 [18JY], H3855 [19JY], H4273 [13SE], H4301 [14SE], H4373 [18SE], H4391, H4396 [19SE], H5233 [2NO], H5882 [15NO], H5977, H5978 [29NO], H6077 [1DE], H6203–H6206 [6DE], E93 [6FE], E629 [30JN]

——— evaluation of administration relative to use of Defense Production Act to boost domestic production of essential medical supplies and medicines, H5933 [28NO]

——— impeachment (H. Res. 493), H2819 [13JN]

CBO: certify that termination of CDC requirement for proof of coronavirus vaccination for foreign travelers will not result in decrease to Social Security benefits, H725 [7FE]

CDC: clarify authority to mandate disease vaccination requirements for foreign travelers, H753 [8FE]

——— clarify that termination of requirement for proof of coronavirus vaccination for foreign travelers shall not impact order to require negative pre-departure coronavirus test for travelers from China, H755, H756 [8FE]

——— eliminate prohibition on future rulemaking relative to requirement for proof of coronavirus vaccination for foreign travelers, H754, H755 [8FE]

——— prohibit funding to implement, promote, or enforce recommendation to add coronavirus vaccine to child and adolescent immunization schedule, H5822 [14NO]

——— report to Congress number of visitors denied entry to U.S. under policy requiring proof of coronavirus vaccination for foreign travelers, H754 [8FE]

——— terminate requirement for proof of coronavirus vaccination for foreign travelers (H.R. 185), H652 [2FE], H747–H762 [8FE], E103 [7FE], E113 [9FE]

——— terminate requirement for proof of coronavirus vaccination for foreign travelers (H.R. 185), consideration (H. Res. 97), H720–H728 [7FE]

Centers for Medicare & Medicaid Services: prohibit funding to enforce coronavirus vaccine reporting requirements for ambulatory surgical centers, H5852, H5853 [14NO]

China: impose sanctions on Chinese producers of synthetic opioids and opioid precursors and hold Chinese officials accountable for spread of illicit fentanyl (H.R. 3203), H3910–H3913 [25JY]

Colleges and universities: prohibit funding for enforcement of coronavirus vaccine mandate as condition of employment or enrollment at institutions of higher education, H5819, H5820 [14NO]

Congress: accomplishments of 117th Congress, H4283–H4289 [13SE]

——— goals of 118th Congress, H5051 [25OC]

Credo Community Center for Treatment and Addictions, Inc.: anniversary, E894 [27SE]

Crime: address nationwide increase in violent crime, H146 [10JA]

——— combat fentanyl crisis, H4395 [19SE]

——— combat opioid crisis, H5233 [2NO]

——— combat trafficking of illicit fentanyl, H588 [1FE], H742 [8FE], H3630 [17JY]

——— reduce threshold for mandatory minimum penalties for certain fentanyl-related offenses (H.R. 335), H2320 [15MY]

DEA: include fentanyl-related substances under schedule I of Controlled Substances Act, designating they have high potential for abuse and no medical use (H.R. 568), H588 [1FE]

——— make permanent scheduling of fentanyl-related substances (H.R. 467), H2485 [22MY], H2507, H2532 [23MY], H2553, H2560, H2561, H2579–H2587, H2591, H2592 [24MY], H2602–H2606, H2625 [25MY], H4353 [18SE], H6745 [11DE], E494, E496, E498 [25MY]

——— make permanent scheduling of fentanyl-related substances (H.R. 467), consideration (H. Res. 429), H2512–H2522 [23MY]

Defense Health Agency: decision by Express Script Holding Co., to eliminate option for TRICARE beneficiaries to obtain prescriptions at pharmacy of their choice, H477–H481 [27JA], H519 [31JA]

Democratic Party: national agenda, H1122 [7MR], H3629 [17JY]

Dept. of Agriculture: prioritize projects that provide behavioral and mental health treatment services in selecting grantees under certain rural development programs and extend substance abuse disorder set-aside (H.R. 4603), H3862 [20JY]

Dept. of Defense: ensure that active-duty service members suffering from traumatic brain injuries are eligible for clinical trials to study effectiveness of psychedelic substances, H4597 [27SE]

——— include in research on fentanyl as schedule I drug, H2603, H2604 [25MY]

——— plant-based or psychedelic medical clinical trials funding, H4596, H4597 [27SE]

——— prohibit provision of gender transition procedures, including surgery or medication, through Exceptional Family Member Program, H3510, H3511 [13JY]

——— prohibit provisions of gender transition procedures, including surgery or medication, through Exceptional Family Member Program, H4616, H4617 [27SE]

——— prohibit TRICARE coverage of sex reassignment surgeries and hormone treatment for transgender individuals, H3508, H3509 [13JY]

——— study and report on health conditions arising in members of Armed Forces after administration of coronavirus vaccine, H3538, H3539 [13JY]

Dept. of Education: study student mental health at institutions of higher education and issue guidance on compliance with Americans With Disabilities Act for mental health and substance use disorder policies, H2385 [17MY]

Dept. of HHS: certify that termination of CDC requirement for proof of coronavirus vaccination for foreign travelers will not result in increase in hospitalizations, H756 [8FE]

——— establish programs to address addiction and overdoses caused by illicit fentanyl and other opioids (H.R. 3375), H2581, H2584 [24MY]

——— expand and clarify exclusion for orphan drugs under drug price negotiation program (H.R. 5539), H5673 [13NO]

——— funding for States to build or maintain their own medical stockpile through reductions in Strategic National Stockpile funding, H5784 [14NO]

——— improve Organ Procurement and Transplantation Network (H.R. 2544), H3929, H3930 [25JY]

——— increase access to mental health, substance use, and counseling services for first responders (H.R. 6415), H5734 [14NO]

——— prohibit from treating pregnancy as illness for purposes of approving abortion drugs (H.R. 6635), H6825 [12DE]

——— Project BioShield funding through reductions in buildings and facilities funding, H5782, H5783 [14NO]

——— promote price transparency in health care sector (H.R. 5378), H4417 [20SE], H6762–H6789 [11DE], H6842 [12DE], E1207 [12DE]

——— reauthorize certain programs relative to mental health and substance use disorders, H2584 [24MY]

——— reauthorize program of preventing overdoses of controlled substances, H6821 [12DE]

——— Strategic National Stockpile funding through reductions in buildings and facilities funding, H5783, H5784 [14NO]

Dept. of Homeland Security: fentanyl smuggling detection and interdiction funding through reduction in border wall infrastructure funding, H4673 [27SE]

——— improve collection of intelligence relative to activities by drug trafficking organizations in certain foreign countries, H2278 [11MY]

——— U.S. Customs and Border Protection funding to study expanded use of canine units for detecting drugs and migrants along southern border, H4646 [27SE]

Dept. of HUD: funding for public housing authorities to conduct drug testing as condition of receiving benefits, H5503 [7NO]

Dept. of Justice: expedite rule-making process of permanent scheduling of fentanyl-related substances, H2603 [25MY]

——— prioritize veterans court treatment programs that ensure equal access for racial and ethnic minorities and women (H.R. 232), E1083 [9NO]

——— provide outreach regarding fentanyl, expand Comprehensive Opioid Abuse Grant Program and addiction treatment and recovery services, and enhance penalties for certain offenses involving counterfeit pills (H.R. 3570), H2486 [22MY], H2520 [23MY]

——— provide outreach regarding fentanyl, expand Comprehensive Opioid Abuse Grant Program and addiction treatment and recovery services, and enhance penalties for certain offenses involving counterfeit pills (H.R. 4272), H3130 [23JN]

Dept. of Labor: reduce salary of Assistant Sec. of Labor for Occupational Safety and Health, H5835 [14NO]

Dept. of State: assess role of Chinese Communist Party in distribution of fentanyl in U.S. (H.R. 3598), H2955 [15JN]

——— impose sanctions with respect to Chinese officials determined to be involved in Mexican fentanyl trade (H.R. 5448), H4275 [13SE]

——— submit report on designation of Reynosa/Los Metros faction of Gulf Cartel, Jalisco New Generation Cartel, Sinaloa Cartel, and Cartel Del Noreste faction of Los Zetas as foreign terrorist organizations (H.R. 1564), H1268 [10MR]

Dept. of Veterans Affairs: authorize health care providers to provide recommendations and opinions to veterans regarding participation in State marijuana programs, H4000–H4002 [26JY]

——— authorize health care providers to provide recommendations and opinions to veterans regarding participation in State marijuana programs (H.R. 2431), E284 [30MR]

——— conduct studies into efficacy of drugs that have FDA-designated Breakthrough Therapy status to treat post-traumatic stress disorder, H3996 [26JY]

——— prohibit funding to enforce Veterans Health Administration directive relative to coronavirus vaccine mandates, H4003, H4004 [26JY]

Depts. of HHS and Justice: certify that making permanent scheduling of fentanyl-related substances will lead to reduction in overdose deaths, H2604, H2605 [25MY]

Depts. of Labor, HHS, and Education, and related agencies: prohibit funding to establish, implement, or enforce any vaccine mandate, H5848 [14NO]

Diseases and disorders: comparison between responses of California and Florida to coronavirus pandemic, H618 [1FE]

——— eliminate coronavirus vaccine mandate on health care providers furnishing items and services under certain Federal health care programs (H.R. 497), H539–H551 [31JA], H583 [1FE], E81 [1FE]

——— eliminate coronavirus vaccine mandate on health care providers furnishing items and services under certain Federal health care programs (H.R. 497), consideration (H. Res. 75), H520–H529 [31JA]

——— President’s Emergency Plan for AIDS (PEPFAR) funding, H4721 [28SE]

——— study safety of coronavirus vaccines, H900 [27FE]

Drug abuse: provide for opioid use disorder prevention, recovery, and treatment, H2580 [24MY]

——— provide for opioid use disorder prevention, recovery, and treatment (H.R. 4531), H6789–H6798 [11DE], H6821 [12DE]

Executive Office of the President: Office of National Drug Control Policy High Intensity Drug Trafficking Areas Program funding, H5658 [9NO]

FAA: require airlines to reinstate pilots who were fired or forced to resign because of vaccine mandates, H3820 [19JY]

FDA: allow for hemp-derived cannabidiol and hemp-derived cannabidiol containing substances in dietary supplements and food (S. 2451), E705 [24JY]

——— allow women greater access to wider range of self-administered contraceptives (H.R. 1512), H1263 [10MR]

——— approval of Leqembi to treat Alzheimer’s disease patients, H3183 [11JY]

——— encourage sponsors of oral contraceptive drugs to submit applications for approval of such drugs as over-the-counter (H.R. 4626), H3617 [17JY]

——— modernize methods of authenticating controlled substances in pharmaceutical distribution supply chain (H.R. 4988), H5973 [29NO]

——— nullify modifications made to risk evaluation and mitigation strategy for abortion pill mifepristone, H4510 [26SE]

——— preserve access to abortion medications, H472 [27JA], H1743 [17AP], H1874, H1875 [19AP], H1889, H1896, H1898 [20AP]

——— prohibit funding for grants relative to any transgenic edible vaccine, H4560 [26SE]

——— prohibit Unapproved Drugs Initiative implementation funding, H4542 [26SE]

——— prohibit use and distribution of abortion drugs, H3901 [25JY]

——— reauthorize user fee programs relating to new animal drugs and generic new animal drugs (H.R. 1418), H3620–H3624 [17JY]

——— reduce salary of Center for Drug Evaluation and Research Director, H4559 [26SE]

——— reduce salary of Division of Risk Management Director, H4562 [26SE]

——— reduce salary of Office of Compliance Director, H4562 [26SE]

——— reduce salary of Office of Medical Policy Director, H4563 [26SE]

——— reduce salary of Office of New Drugs Director, H4562 [26SE]

——— reduce salary of Office of Regulatory Policy Director, H4563 [26SE]

——— reduce salary of Office of Surveillance and Epidemiology Director, H4561 [26SE]

Federal agencies and departments: include any rule likely to increase mandatory vaccinations in requirement for congressional joint resolution of approval for major rules, H2914, H2915 [14JN]

——— prohibit from imposing any mandate requiring individuals to receive vaccine that has not been authorized for marketing for at least 10 years (H.R. 2631), H2044 [26AP]

——— provide for greater accountability relative to Federal activities and expenditures relating to coronavirus (H.R. 271), H159 [11JA]

Fentanyl Prevention Caucus: launch, H1254 [10MR]

Foreign policy: report on congressional delegation trip to Brazil, Columbia, and Panama, H3901 [25JY]

GAO: study trafficking of synthetic drugs into U.S. and related illicit finance (H.R. 1076), H2469–H2471 [22MY]

Georgia: tribute to law enforcement efforts, H885 [27FE]

Harris, Vice President: impeachment (H. Res. 494), H2819 [13JN]

Health: address health risks associated with Delta–8 THC derived from cannabis, H5470 [7NO]

——— reduce prescription drug and health care costs, H805 [9FE]

House of Representatives: legislative priorities, H518 [31JA], H5954 [29NO], H6199 [6DE]

Immigration: recognize State sovereign power to repel invasion and defend citizenry from overwhelming and imminent danger posed by paramilitary, narco-terrorist cartels at southern border, H4648, H4649 [27SE]

——— secure U.S. borders and reform immigration policies, H4861, H4890, H4894, H4895 [29SE], H6065 [1DE]

——— secure U.S. borders and reform immigration policies (H.R. 2), H2178, H2195–H2236 [10MY], H2249, H2250, H2255, H2258–H2281, H2296, H2297 [11MY], H2354, H2355 [16MY], H2384, H2420 [17MY], H2443 [18MY], H2485 [22MY], H2559 [24MY], H3010 [21JN], H4125–H4128 [27JY], H4273 [13SE], H4301 [14SE], H4418 [20SE], H4486, H4488–H4494 [26SE], H4681, H4682 [27SE], H4795 [28SE], H4936, H4940 [2OC], H5233 [2NO], H5908 [28NO], H5944, H5947, H5963, H5964, H5970, H5978 [29NO], H6034, H6036 [30NO], H6139 [5DE], H6202 [6DE], H6803 [11DE], H6826, H6827, H6848 [12DE], H6930, H6934 [13DE], H6973, H6975, H6976 [14DE], E419 [10MY], E436 [15MY]

——— secure U.S. borders and reform immigration policies (H.R. 2), consideration (H. Res. 383), H2183–H2195 [10MY]

Inflation Reduction Act: impact, H653 [2FE]

Insulin: limit price charged by manufacturers for insulin, H5715 [13NO]

Insurance: apply additional payments, discounts, and other financial assistance towards cost-sharing requirements of health insurance plans (H.R. 830), H2466 [22MY], E249 [23MR]

——— establish requirements relative to cost-sharing for certain insulin products, E1105 [15NO]

——— establish requirements relative to cost-sharing for certain insulin products for children, H2983 [20JN]

Law enforcement: use forfeited criminal proceeds resulting from prosecution of Joaquín A. Guzmán Loera (El Chapo) or other felony drug convictions for border security measures, including border wall (H.R. 1793), H2278 [11MY]

Marijuana: decriminalize, H3114 [23JN]

Mayorkas, Sec. of Homeland Security: impeachment, H5663 [9NO]

Medicaid: prohibit funding to finalize, implement, or enforce proposed rule relative to drug rebate program, H5837 [14NO]

Medicare: coordinate programs to prevent and treat obesity (H.R. 4818), H3956 [26JY]

——— establish improved Medicare for All national health insurance program (H.R. 3421), H2560 [24MY], H4043 [27JY]

——— selection of certain Medicare part D drugs for negotiation under Drug Price Negotiation Program, H4238 [12SE]

Mental health: strengthen parity in mental health and substance use disorder benefits, H2385 [17MY]

Mexico: limit availability of certain funds for Mexico until President makes certification to Congress regarding cooperation by Mexico with respect to fentanyl (H.R. 3190), H4428 [20SE]

Mobilize Recovery Across Georgia (organization): tribute, H4428 [20SE]

National Highway Traffic Safety Administration: prohibit funding to implement advanced impaired driving technology motor vehicle safety standard, H5519–H5521 [7NO]

National objectives: improve health care services, H1742 [17AP]

NIST: coordinate science and research activities relative to illicit drugs containing xylazine, novel synthetic opioids, and other substances of concern (H.R. 1734), H1335 [23MR], H2149–H2151 [9MY], H3214 [12JY]

——— coordinate science and research activities relative to illicit drugs containing xylazine, novel synthetic opioids, and other substances of concern (H.R. 1734), Senate amendment, H6087–H6089 [4DE]

Ohio: tribute to Ohio Narcotics Intelligence Center, H3495 [13JY]

Pharmaceuticals: address prescription drug shortages, H1471 [28MR], H4468 [26SE]

——— clarify Federal Right To Try laws apply to schedule 1 substances for which phase 1 clinical trial has been completed and provide access to eligible patients to such substances (H.R. 1825), E267 [28MR]

——— decision by manufacturers to cap patient out-of-pocket costs for insulin, H1535 [29MR]

——— support fair pricing in coronavirus vaccine sales, H293 [25JA]

Prematurity Research Expansion and Education for Mothers Who Deliver Infants Early (PREEMIE) Act: reauthorize (H.R. 3226), H6799, H6800 [11DE]

Rare Disease Day: designate (H. Res. 181), E161 [28FE]

Republican Party: national agenda, H585 [1FE], H4124–H4128 [27JY], H5157–H5161 [26OC]

Rocky Mount, NC: express condolences to victims of and commend response to tornado affecting Pfizer, Inc., facility, and recognize company’s continued investment in local economy, H4016 [26JY]

Social Security: reform, H589 [1FE], H653, H654 [2FE]

Syria: require U.S. strategy to disrupt and dismantle Captagon trade and narcotics networks linked to regime of Bashar al-Assad, H2445 [18MY], E612 [23JN]

Taxation: allow deductions and credits relating to expenditures in connection with marijuana sales conducted in compliance with State law (H.R. 2643), E320 [17AP]

Technology: invest in current technologies that streamline Federal programs, increase carbon reduction, and aid in development of vaccines, H6852–H6854 [12DE]

Texas: tribute to 6th Congressional District outstanding constituents, H4338 [14SE]

‘‘War on Drugs’’: impact, H2582, H2583 [24MY]

Remarks in Senate

Abortion: Texas Federal district court decision in Alliance for Hippocratic Medicine v. FDA relative to approval of abortion pill mifepristone, S1123 [17AP]

——— Texas Federal district court hearing of Alliance for Hippocratic Medicine v. FDA relative to approval of abortion pill mifepristone, S416 [15FE], S438–S441 [16FE], S836 [16MR]

Armed Forces: provide remedies to members discharged or subject to adverse action under coronavirus vaccine mandate (S. 29), S248 [7FE]

Biden, President: evaluation of administration relative to abortion, S2172–S2174 [21JN]

——— evaluation of administration relative to immigration, S11 [3JA], S46–S49 [23JA], S84–S92 [25JA], S154–S157 [31JA], S333 [13FE], S446–S448 [16FE], S515 [28FE], S622 [2MR], S649 [6MR], S662 [7MR], S732, S735 [9MR], S763, S766 [14MR], S886, S888–S891 [22MR], S1063, S1075–S1077 [30MR], S1125, S1127 [17AP], S1230 [19AP], S1407 [27AP], S1544 [4MY], S1611, S1612 [11MY], S1638 [15MY], S1656 [16MY], S1687, S1693–S1697 [17MY], S1724–S1726 [18MY], S2152–S2154 [21JN], S2270 [10JY], S2294–S2296 [11JY], S2334–S2336 [12JY], S2450–S2452 [13JY], S3438 [20JY], S3564 [26JY], S4259–S4261, S4328–S4330 [7SE], S4513 [14SE], S4544 [18SE], S4577 [19SE], S4645 [21SE], S4672 [26SE], S4692–S4694, S4697 [27SE], S4736, S4742 [28SE], S4933–S4935 [4OC], S5075 [18OC], S5095 [19OC], S5127, S5129 [24OC], S5166 [25OC], S5223–S5225 [30OC], S5271, S5272 [1NO], S5329 [2NO], S5353–S5355 [6NO], S5373 [7NO], S5415 [8NO], S5471, S5474 [13NO], S5517 [15NO], S5620 [28NO], S5647–S5649, S5653, S5655, S5656–S5661 [29NO], S5683, S5687 [30NO], S5701, S5704 [4DE], S5769, S5771 [6DE], S5892 [11DE], S5937, S5938 [13DE]

——— evaluation of administration relative to prescription drug costs, S5904 [12DE]

——— meeting with Chinese President Xi Jinping, S5515, S5517 [15NO]

——— State of the Union Message, S245, S249 [7FE]

CDC: terminate requirement for proof of coronavirus vaccination for foreign travelers (H.R. 185), S332 [9FE], S361 [13FE], S896–S898 [22MR], S1073–S1075 [30MR]

——— terminate requirement for proof of coronavirus vaccination for foreign travelers (H.R. 185), unanimous-consent request, S897 [22MR], S1074 [30MR]

Children and youth: prohibit certain coronavirus vaccination mandates and require parental consent for vaccination of minors (S. 169), S248 [7FE]

China: analysis of U.S.-China relations, S1994 [7JN]

——— recognize as greatest foreign threat to U.S. peace, security, and stability, S5495 [14NO]

——— take action to stop sale and export of fentanyl precursors, S5515 [15NO]

——— U.S. policy, S5465 [13NO], S5481 [14NO]

Committee on Foreign Investment in the U.S.: increase oversight of foreign direct investment in U.S. agricultural land (S. 1066), S978 [28MR]

Controlled Substances Act: amend to fix technical error in definitions (S. 223), S192 [1FE]

Courts: increase mandatory minimum sentencing penalties for drug traffickers and dealers convicted for distribution of fentanyl (S. 878), S1557–S1560 [9MY]

——— increase mandatory minimum sentencing penalties for drug traffickers and dealers convicted for distribution of fentanyl (S. 878), unanimous-consent request, S1559, S1560 [9MY]

Crime: address nationwide increase in violent crime, S411 [15FE]

——— combat trafficking of illicit fentanyl, S732 [9MR], S1231–S1233 [19AP], S1407 [27AP], S3875 [5SE], S4259 [7SE]

——— prohibit certain acts related to fentanyl, analogues of fentanyl, and counterfeit substances (S. 1475), S1563 [9MY]

——— punish distribution of fentanyl resulting in death as felony murder (S. 380), S3876 [5SE]

DEA: anniversary (S. Res. 246), S3121 [18JY]

——— include fentanyl-related substances under schedule I of Controlled Substances Act, designating they have high potential for abuse and no medical use (S. 600), S1231 [19AP]

Dept. of Defense: effect of coronavirus vaccine mandate, S4341 [11SE]

Dept. of HHS: establish program to support health care providers and pharmacies in providing discounted insulin products to uninsured individuals (S. 954), S5498–S5500 [14NO]

——— improve Organ Procurement and Transplantation Network (H.R. 2544), S3731–S3733 [27JY]

——— improve Organ Procurement and Transplantation Network (H.R. 2544), unanimous-consent request, S3731, S3732 [27JY]

——— improve Organ Procurement and Transplantation Network (S. 1668), S5940, S5941 [13DE]

——— provide authority to suspend right to introduce certain persons or property into U.S. in interest of public health (S. 1192), S1257 [19AP], S1435 [1MY], S1585, S1586 [10MY]

——— provide authority to suspend right to introduce certain persons or property into U.S. in interest of public health (S. 1192), unanimous-consent request, S1586 [10MY]

——— provide for appropriate cost-sharing for insulin products covered under Medicare part D and private health plans, S219 [2FE], S616 [2MR], S756 [14MR], S810 [16MR]

——— provide for appropriate cost-sharing for insulin products covered under private health plans (S. 954), S5498–S5500 [14NO]

——— reauthorize and expand technical assistance and support for recovery community organizations and peer support networks (S. 3259), S5429 [8NO]

Dept. of HUD: authorize grant program to assist State and local governments, continuums of care, and community-based organizations that administer health and homelessness services to better coordinate those services (S. 3165), S5231 [30OC]

Dept. of Justice: authorize use of grants to provide training for first responders on use of containment devices to prevent exposure to fentanyl and other potentially lethal substances and for purchasing such devices (S. 261), S1641 [15MY]

——— provide grants to State and local law enforcement agencies to purchase chemical screening devices to detect dangerous drugs and train personnel on use of such devices (S. 1507), S1641 [15MY]

——— require electronic communication service providers and remote computing services to report unlawful sale and distribution of controlled substances (S. 1080), S1563 [9MY], S3454 [20JY]

Dept. of State: designate Mexican cartels and other transnational criminal organizations as foreign terrorist organizations (S. 1048), S1559 [9MY]

Dept. of the Treasury: impose sanctions with respect to trafficking of illicit fentanyl and its precursors by transnational criminal organizations, including cartels, S3737 [27JY], S3876 [5SE], S5700 [4DE]

Dept. of Veterans Affairs: carry out clinical trial of effects of cannabis on certain health outcomes of adults with chronic pain and post-traumatic stress disorder (S. 326), S1354 [26AP]

——— carry out clinical trial of effects of cannabis on certain health outcomes of adults with chronic pain and post-traumatic stress disorder (S. 326), motion to proceed, S1359, S1360 [26AP]

Diseases and disorders: end coronavirus vaccine mandates, S247–S249 [7FE]

——— President’s Emergency Plan for AIDS (PEPFAR) funding, S5221 [30OC]

——— prohibit vaccination mandates for coronavirus (S. 167), S248 [7FE]

District of Columbia: prohibit use of Federal and local funds for coronavirus vaccine mandate in District of Columbia schools and repeal related legislation enacted by District of Columbia Council (S. 165), S248 [7FE]

Drug abuse: address drug abuse epidemic by securing southern border, S1229 [19AP]

Economy: national objectives priority assignments, S3577–S3579 [26JY]

FDA: establish time-limited conditional approval pathway, subject to specific obligations, for certain drugs and biological products, S412 [15FE]

——— improve regulation of abortion drugs by prohibiting approval of new drugs, preventing labeling changes of existing drugs, and limiting dispensing of drugs remotely, by mail, or telemedicine, S68, S69 [24JA]

——— preserve access to abortion medications, S630 [2MR]

——— reauthorize user fee programs relating to new animal drugs and generic new animal drugs (S. 1844), S5038 [17OC]

FEMA: prohibit award of firefighter assistance grants to fire departments that dismissed employees for not complying with coronavirus vaccine mandate, S1225, S1226 [19AP]

Fentanyl Prevention and Awareness Day: support goals and ideals (S. Res. 323), S3839 [27JY]

Financial institutions: create protections for financial institutions that provide financial services to State-sanctioned marijuana businesses and service providers for such businesses (S. 1323), S1404 [27AP]

——— create protections for financial institutions that provide financial services to State-sanctioned marijuana businesses and service providers for such businesses (S. 2860), S4690 [27SE], S4730 [28SE]

Firearms: gun control, S4706 [27SE]

First Step Act: impact, S5972–S5975 [14DE]

Health: prohibit consideration of coronavirus vaccination status in determining eligibility for organ donation or transplantation and in providing services to Medicare or Medicaid beneficiaries (S. 164), S248 [7FE]

——— prohibit consideration of race, color, religion, sex, national origin, age, disability, vaccination status, veteran status, political ideology, or speech in determining eligibility for coronavirus treatments and vaccines (S. 171), S248 [7FE]

——— protect individual liberty, ensure privacy, and prohibit discrimination relative to coronavirus vaccination status of individuals (S. 181), S248 [7FE]

Immigration: prohibit individuals charged with or convicted of human trafficking or drug trafficking offenses committed near border from receiving Federal benefits (S. 519), S515 [28FE], S1128 [17AP]

——— recognize current influx of migrants is causing crisis at U.S. Southern border (S. Res. 45), S735 [9MR]

——— reform, S5885 [11DE]

——— secure U.S. borders and reform immigration policies, S1885 [1JN], S5371 [7NO], S5516 [15NO], S5682 [30NO], S5701–S5703 [4DE], S5768 [6DE], S5902, S5905 [12DE], S5927–S5930 [13DE], S5970 [14DE], S6013, S6014 [18DE], S6031, S6036, S6038 [19DE], S6071–S6073 [20DE]

——— secure U.S. borders and reform immigration policies (H.R. 2), S1580 [10MY], S1655 [16MY]

——— secure U.S. borders and reform immigration policies (S. 2824), S4578 [19SE]

Inflation Reduction Act: impact, S189 [1FE], S4213 [6SE], S5722–S5725 [5DE], S5903 [12DE]

Insulin: reduce price of insulin, require pharmacy benefit managers to pass-through manufacturer rebates for insulin products, and promote generic and biosimilar competition (S. 1269), S1332–S1334 [25AP]

Insurance: provide for increased oversight of entities that provide pharmacy benefit management services on behalf of group health plans and health insurance coverage, S4735 [28SE]

Kansas: tribute to One Pill Can Kill fentanyl awareness campaign, S4222 [6SE]

Kentucky: legislative priorities, S3871 [5SE]

Medicare: anniversary of Part D prescription drug benefit, S5841, S5842 [7DE]

——— implementation of drug price negotiation program, S3877 [5SE], S4245–S4247 [7SE], S4374–S4380 [12SE], S4610, S4611 [20SE]

——— improve access to opioid use disorder treatment services (S. 3326), S5549 [15NO]

Medicare/Medicaid: lower prescription drug prices, improve transparency of pharmaceutical prices and transactions, lower patients’ out-of-pocket costs, and ensure accountability to taxpayers, S645 [6MR]

——— require drug and biological product manufacturers to include truthful and non-misleading pricing information in any direct-to-consumer advertising (S. 1250), S1297 [20AP], S4246 [7SE], S5624–S5627 [28NO]

——— require drug and biological product manufacturers to include truthful and non-misleading pricing information in any direct-to-consumer advertising (S. 1250), unanimous-consent request, S5625 [28NO]

Mexico: express concern about economic and security conditions and reaffirm interest in mutually beneficial relations based on shared interests on security, economic prosperity, and democratic values, S5726, S5727 [5DE]

——— express concern about economic and security conditions and reaffirm interest in mutually beneficial relations based on shared interests on security, economic prosperity, and democratic values (S. Res. 97), S843 [21MR]

National Fentanyl Awareness Day: designate (S. Res. 215), S1712 [17MY]

——— observance, S1563 [9MY]

National Naloxone Awareness Day: designate (S. Res. 250), S2076 [13JN]

National objectives: improve health care services, S4342 [11SE], S5382 [7NO]

National Recovery Month: observance, S4649 [21SE]

NIST: coordinate science and research activities relative to illicit drugs containing xylazine, novel synthetic opioids, and other substances of concern (H.R. 1734), S2250 [22JN]

Pharmaceuticals: address prescription drug shortages, S2023–S2025 [8JN]

——— decision by manufacturers to cap patient out-of-pocket costs for insulin, S616 [2MR], S645 [6MR], S756 [14MR], S810 [16MR]

——— limit role of pharmacy benefit managers and support market-based pricing, S3440–S3442 [20JY]

——— lower prescription drug costs for consumers, S412–S414 [15FE], S616 [2MR], S4644 [21SE]

——— prohibit prescription drug manufacturers from compensating other companies to delay entry of generic drugs, biosimilar biological products, or interchangeable biological products into market (S. 142), S218 [2FE]

Red Ribbon Week: support goals and ideals (S. Res. 449), S5336 [2NO]

Senate: legislative priorities, S1736 [18MY], S1778 [30MY], S1970 [6JN], S1996 [7JN], S3869 [5SE], S4902 [3OC], S5198 [26OC]

——— legislative program, S2267 [10JY]

——— prohibit imposition of vaccination, testing, and masking requirements relative to coronavirus for Senate Pages (S. Res. 332), S4248–S4252 [7SE]

——— prohibit imposition of vaccination, testing, and masking requirements relative to coronavirus for Senate Pages (S. Res. 332), unanimous-consent request, S4251 [7SE]

——— prohibit imposition of vaccination requirements relative to coronavirus for Senate Pages (S. Res. 336), S4369–S4372 [12SE], S4572–S4575 [19SE], S5943–S5946 [13DE]

——— prohibit imposition of vaccination requirements relative to coronavirus for Senate Pages (S. Res. 336), unanimous-consent request, S4371 [12SE], S4574 [19SE], S5944, S5945 [13DE]

Reports

Office of National Drug Control Policy Should Develop Key Planning Elements To Meet Statutory Requirements: GAO, H2514–H2516 [23MY]

Reports filed

Affordable Prescriptions for Patients Act: Committee on the Judiciary (Senate) (S. 150), S567 [1MR]

Better Mental Health Care, Lower-Cost Drugs, and Extenders Act: Committee on Finance (Senate) (S. 3430) (S. Rept. 118–121), S5850 [7DE]

Block, Report, and Suspend Suspicious Shipments Act: Committee on Energy and Commerce (House) (H.R. 501) (H. Rept. 118–66), H2422 [17MY]

Caribbean Basin Security Initiative Appropriations, U.S.-Caribbean Security Partnership Enhancement, and Disaster Resilience Prioritization: Committee on Foreign Relations (Senate) (S. 841), S1533 [4MY]

Consideration of H.R. 2, Secure the Border Act: Committee on Rules (House) (H. Res. 383) (H. Rept. 118–51), H2243 [10MY]

Consideration of H.R. 185, Terminate CDC Requirement for Proof of Coronavirus Vaccination for Foreign Travelers: Committee on Rules (House) (H. Res. 97) (H. Rept. 118–3), H737 [7FE]

Consideration of H.R. 467, Halt All Lethal Trafficking of (HALT) Fentanyl Act: Committee on Rules (House) (H. Res. 429) (H. Rept. 118–76), H2498 [22MY]

Consideration of H.R. 497, Freedom for Health Care Workers Act: Committee on Rules (House) (H. Res. 75) (H. Rept. 118–1), H574 [31JA]

Enhancing DHS Drug Seizures Act: Committee on Homeland Security and Governmental Affairs (Senate) (S. 1464) (S. Rept. 118–104), S4916 [3OC]

Ensuring Timely Access to Generics Act: Committee on Health, Education, Labor, and Pensions (Senate) (S. 1067), S2221 [22JN]

Expanding Access to Low-Cost Generics Act: Committee on Health, Education, Labor, and Pensions (Senate) (S. 1114), S2221 [22JN]

FDA User Fee Programs Relating to New Animal Drugs and Generic New Animal Drugs Reauthorization: Committee on Energy and Commerce (House) (H.R. 1418) (H. Rept. 118–104), H2785 [9JN]

——— Committee on Health, Education, Labor, and Pensions (Senate) (S. 1844), S3618 [26JY]

Fentanyl Eradication and Narcotics Deterrence (FEND) Off Fentanyl Act: Committee on Banking, Housing, and Urban Affairs (Senate) (S. 1271), S2221 [22JN]

Halt All Lethal Trafficking of (HALT) Fentanyl Act: Committee on Energy and Commerce (House) (H.R. 467) (H. Rept. 118–67), H2423 [17MY]

Interagency Patent Coordination and Improvement Act: Committee on the Judiciary (Senate) (S. 79), S567 [1MR]

Kids First Research Act 2.0: Committee on Health, Education, Labor, and Pensions (Senate) (S. 1624), S4947 [4OC]

Modernizing and Ensuring PBM Accountability Act: Committee on Finance (Senate) (S. 2973) (S. Rept. 118–122), S5850 [7DE]

Pandemic and All-Hazards Preparedness and Response Act: Committee on Health, Education, Labor, and Pensions (Senate) (S. 2333), S4227 [6SE]

Pharmacy Benefit Manager Reform Act: Committee on Health, Education, Labor, and Pensions (Senate) (S. 1339), S2221 [22JN]

Pharmacy Benefit Manager Transparency Act: Committee on Commerce, Science, and Transportation (Senate) (S. 127), S5960 [13DE]

Prematurity Research Expansion and Education for Mothers Who Deliver Infants Early (PREEMIE) Act Reauthorization: Committee on Energy and Commerce (House) (H.R. 3226) (H. Rept. 118–164), H4203 [25AU]

——— Committee on Health, Education, Labor, and Pensions (Senate) (S. 1573), S4947 [4OC]

Prescription Pricing for the People Act: Committee on the Judiciary (Senate) (S. 113), S567 [1MR]

Preserve Access to Affordable Generics and Biosimilars Act: Committee on the Judiciary (Senate) (S. 142), S567 [1MR]

Preventing the Financing of Illegal Synthetic Drugs Act: Committee on Financial Services (House) (H.R. 1076) (H. Rept. 118–75), H2498 [22MY]

Protecting the Border From Unmanned Aircraft Systems Act: Committee on Homeland Security and Governmental Affairs (Senate) (S. 1443) (S. Rept. 118–103), S4916 [3OC]

Require Electronic Communication Service Providers and Remote Computing Services To Report Unlawful Sale and Distribution of Controlled Substances: Committee on the Judiciary (Senate) (S. 1080), S3894 [5SE]

Retaining Access and Restoring Exclusivity (RARE) Act: Committee on Health, Education, Labor, and Pensions (Senate) (S. 1214), S2221 [22JN]

Secure and Fair Enforcement Regulation (SAFER) Banking Act: Committee on Banking, Housing, and Urban Affairs (Senate) (S. 2860), S4759 [28SE]

Securing the Border for Public Health Act: Committee on Energy and Commerce (House) (H.R. 801) (H. Rept. 118–53), H2306 [11MY]

Securing the U.S. Organ Procurement and Transplantation Network Act: Committee on Energy and Commerce (House) (H.R. 2544) (H. Rept. 118–140), H3204 [11JY]

Stop Significant and Time-Wasting Abuse Limiting Legitimate Innovation of New Generics (Stop STALLING) Act: Committee on the Judiciary (Senate) (S. 148), S567 [1MR]

Testing, Rapid Analysis, and Narcotic Quality (TRANQ) Research Act: Committee on Commerce, Science, and Transportation (Senate) (S. 1280), S5960 [13DE]

——— Committee on Science, Space, and Technology (House) (H.R. 1734) (H. Rept. 118–50), H2133 [5MY]

VA Medicinal Cannabis Research Act: Committee on Veterans’ Affairs (Senate) (S. 326), S931 [23MR]

Statements

International Health Regulations Emergency Committee Regarding the Coronavirus Disease (COVID–19) Pandemic: WHO, H749 [8FE]

Managing SARS-CoV–2 Exposures: CDC, H749 [8FE]

Safety and Compassion Can Exist Without Extreme Measures: Sojourners (publication), H2231 [10MY]

Secure the Border Act: Executive Office of the President, H2234 [10MY]

Terminate CDC Requirement for Proof of Coronavirus Vaccination for Foreign Traveler: Senator Sanders, S1074 [30MR]

Tables

Estimated budget effects of Inflation Reduction Act, H2028 [26AP]

Texts of

H. Res. 75, consideration of H.R. 497, Freedom for Health Care Workers Act, H520 [31JA]

H. Res. 97, consideration of H.R. 185, terminate CDC requirement for proof of coronavirus vaccination for foreign travelers, H720 [7FE]

H. Res. 383, consideration of H.R. 2, Secure the Border Act, H2184 [10MY]

H. Res. 429, consideration of H.R. 467, Halt All Lethal Trafficking of (HALT) Fentanyl Act, H2512 [23MY]

H.R. 2, Secure the Border Act, H2195–H2216 [10MY]

H.R. 185, terminate CDC requirement for proof of coronavirus vaccination for foreign travelers, H752 [8FE]

H.R. 497, Freedom for Health Care Workers Act, H539 [31JA]

H.R. 1076, Preventing the Financing of Illegal Synthetic Drugs Act, H2469 [22MY]

H.R. 1418, FDA user fee programs relating to new animal drugs and generic new animal drugs reauthorization, H3620–H3623 [17JY]

H.R. 1734, Testing, Rapid Analysis, and Narcotic Quality (TRANQ) Research Act, H2149 [9MY]

H.R. 2544, Securing the U.S. Organ Procurement and Transplantation Network Act, H3929 [25JY]

H.R. 3203, Stop Chinese Fentanyl Act, H3910 [25JY]

H.R. 3226, Prematurity Research Expansion and Education for Mothers Who Deliver Infants Early (PREEMIE) Act reauthorization, H6799 [11DE]

H.R. 4531, certain programs to provide for opioid use disorder prevention, recovery, and treatment reauthorization, H6790–H6794 [11DE]

H.R. 5378, Lower Costs, More Transparency Act, H6762–H6785 [11DE]

S. 79, Interagency Patent Coordination and Improvement Act, S102 [25JA]

S. 223, amend Controlled Substances Act to fix technical error in definitions, S192 [1FE]

S. 389, Justice Against Sponsors of Illicit Fentanyl Act, S323 [9FE]

S. 1056, Smarter Pretrial Detention for Drug Charges Act, S1055 [29MR]

S. 1152, Smarter Sentencing Act, S1095 [30MR]

S. 1247, Terry Technical Correction Act, S1296 [20AP]

S. 1250, Drug-Price Transparency for Consumers (DTC) Act, S1297 [20AP]

S. 1251, First Step Implementation Act, S1298–S1304 [20AP]

S. 1991, Comprehensive Addiction Recovery Through Effective Employment and Reentry (CAREER) Act, S2099 [14JN]

S. 2405, Strengthening Pharmacy Access for Seniors Act, S3461 [20JY]

S. 2477, Equitable Community Access to Pharmacist Services Act, S3525 [25JY]

S. Res. 45, recognize current influx of migrants is causing crisis at U.S. Southern border, S328 [9FE]

S. Res. 79, National Fentanyl Awareness Week, S507 [27FE]

S. Res. 97, express concern about economic and security conditions in Mexico and reaffirm interest in mutually beneficial relations based on shared interests on security, economic prosperity, and democratic values, S717 [8MR]

S. Res. 139, recognize critical role that President’s Emergency Plan for AIDS (PEPFAR) has played in global fight against HIV/AIDS, S1096 [30MR]

S. Res. 169, condemn Sec. of Homeland Security Mayorkas for failure to secure U.S. southern border, S1306 [20AP]

S. Res. 180, National Adult Hepatitis B Vaccination Awareness Day, S1422 [27AP]

S. Res. 197, Tardive Dyskinesia Awareness Week, S1537 [4MY]

S. Res. 215, National Fentanyl Awareness Day, S1709 [17MY]

S. Res. 246, DEA anniversary, S2073 [13JN]

S. Res. 250, National Naloxone Awareness Day, S2075 [13JN]

S. Res. 323, support goals and ideals of Fentanyl Prevention and Awareness Day, S3770 [27JY]

S. Res. 332, prohibit imposition of vaccination, testing, and masking requirements relative to coronavirus for Senate Pages, S4272 [7SE]

S. Res. 336, prohibit imposition of vaccination requirements relative to coronavirus for Senate Pages, S4391 [12SE]

S. Res. 383, support goals and ideals of Red Ribbon Week, S4765 [28SE]

S. Res. 449, support goals and ideals of Red Ribbon Week, S5343 [2NO]

S. Res. 510, respect FDA scientific judgement that mifepristone is safe and effective and ensure access to lifesaving, time-sensitive medication abortion care in U.S. is equitable and based on science, S6004 [14DE]